



OPEN ACCESS

EDITED BY

Ruyu Yao,
Chinese Academy of Sciences (CAS), China

REVIEWED BY

Alexander N. Shikov,
Saint-Petersburg State Chemical
Pharmaceutical Academy, Russia
Roy Upton,
American Herbal Pharmacopoeia, United States
Wenjun Zhong,
HerbaSinica Hilsdorf GmbH, Germany

*CORRESPONDENCE

Xuanbin Wang,
✉ wangxb@hbm.u.edu.cn
Rudolf Bauer,
✉ rudolf.bauer@uni-graz.at
Pierre Duez,
✉ pierre.duez@umons.ac.be
Qihe Xu,
✉ qihe.xu@kcl.ac.uk

RECEIVED 09 November 2025

REVISED 04 January 2026

ACCEPTED 05 January 2026

PUBLISHED 09 April 2026

CITATION

Wang X, Li H, Jiang S, Yang N, Wang D, Xu H, Robinson N, Shyur L-F, Heinrich M, Wang M, Simmonds MSJ, Zhong L, Brahmi F, Efferth T, Bakari SA, Lau CB-S, Wong W, Bauer R, Duez P and Xu Q (2026) International standards and good practice guidelines in traditional, complementary and integrative medicine: a scoping review.
Front. Pharmacol. 17:1742400.
doi: 10.3389/fphar.2026.1742400

COPYRIGHT

© 2026 Wang, Li, Jiang, Yang, Wang, Xu, Robinson, Shyur, Heinrich, Wang, Simmonds, Zhong, Brahmi, Efferth, Bakari, Lau, Wong, Bauer, Duez and Xu. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

International standards and good practice guidelines in traditional, complementary and integrative medicine: a scoping review

Xuanbin Wang^{1*}, Hongliang Li¹, Shun Jiang¹, Nian Yang², Dongpeng Wang¹, Hongxi Xu³, Nicola Robinson ^{4,5}, Lie-Fen Shyur⁶, Michael Heinrich^{7,8}, Mei Wang ⁹, Monique S. J. Simmonds¹⁰, Linda Zhong^{11,12}, Fatiha Brahmi¹³, Thomas Efferth¹⁴, Salvius Amuri Bakari¹⁵, Clara Bik-San Lau¹⁶, Wendy Wong¹⁷, Rudolf Bauer^{18*}, Pierre Duez^{19*} and Qihe Xu^{20,21*}

¹Laboratory of Chinese Herbal Pharmacology, Department of Pharmacy, Renmin Hospital, Institute of Biomedicine Research, Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, China, ²The First Affiliated Hospital (Shenzhen People's Hospital), Southern University of Science and Technology, Shenzhen, China, ³School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China, ⁴London South Bank University, London, United Kingdom, ⁵Centre of Evidence Based Medicine, Beijing University of Chinese Medicine, Beijing, China, ⁶Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan, ⁷Research Group 'Pharmacognosy and Phytotherapy', UCL School of Pharmacy, University College London, London, United Kingdom, ⁸Department of Pharmaceutical Sciences and Chinese Medicine Resources, Chinese Medicine Research Center, College of Chinese Medicine, China Medical University, Taichung, Taiwan, ⁹Naturalis Biodiversity Center, and SU BioMedicine B.V., Leiden, Netherlands, ¹⁰Royal Botanic Gardens Kew, London, United Kingdom, ¹¹Biomedical Sciences and Chinese Medicine, School of Biological Sciences, Nanyang Technological University, Singapore, Singapore, ¹²NTU Chinese Medicine Clinic, Nanyang Technological University, Singapore, Singapore, ¹³Laboratory of Biomathematics, Biochemistry, Biophysics and Scientometry, Faculty of Natural and Life Sciences, University of Bejaia, Bejaia, Algeria, ¹⁴Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany, ¹⁵Laboratory of Pharmacognosy, Faculty of Pharmaceutical Sciences, University of Lubumbashi, Lubumbashi, Democratic Republic of Congo, ¹⁶Department of Pharmacology and Pharmacy, and School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China, ¹⁷Jockey Club of School of Public Health and Primary Care, Chinese University of Hong Kong, Hong Kong SAR, China, ¹⁸Institute of Pharmaceutical Sciences, University of Graz, Graz, Austria, ¹⁹Unit of Therapeutic Chemistry and Pharmacognosy, University of Mons (UMONS), Mons, Belgium, ²⁰Department of Inflammation Biology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom, ²¹King's Centre for Integrative Chinese Medicine, James Black Centre, King's College London, London, United Kingdom

Objectives: To map the development of international standards (IS) and international good practice guidelines (IGPG) across the field of traditional, complementary and integrative medicine (TCIM) and establish a comprehensive repository.

Methods: A systematic search was conducted using PubMed, Web of Science, EMBASE, ProQuest, and the Cochrane Library, as well as relevant websites, with the assistance of artificial intelligence tools. This search combined MeSH terms and keywords, and was further supplemented by non-systematic human expert input, covering the period from January 2000 to April 2025. Duplicates were removed and all records were screened based on pre-defined criteria for TCIM-relevant IS/IGPG and TCIM- and IS/IGPG-related systematic reviews, implementation documents and commentaries.

Findings: 2026 records met inclusion criteria: (a) TCIM-relevant IS/IGPG documents (n = 1,624); and (b) TCIM- and IS/IGPG-related secondary

documents (systematic reviews, perspectives and commentaries, $n = 402$). These IS/IGPG were produced by 33 international organisations and consortia, broadly applicable to TCIM or specific to a particular TCIM modality. Our data showed acceleration in IS/IGPG production over the past two decades. An analysis of the secondary literature provided a broad overview of the disease spectrum and the application of IS/IGPG in TCIM studies.

Conclusion: A comprehensive repository for TCIM-related IS/IGPG has been established. These IS/IGPG can be expected to play important roles for an efficient implementation of the World Health Organization Traditional Medicine Strategy 2025–2034. Future work should focus on disseminating, implementing and harmonising these IS/IGPG, evaluating their effectiveness and refining them, while promoting global parity in access, implementation and coverage.

Study Registration: The Open Science Framework (<https://doi.org/10.17605/OSF.IO/H8UFM>).

KEYWORDS

complementary medicine, integrative medicine, international good practice guidelines, international standards, scoping review, traditional medicine

1 Introduction

Ensuring universal access to safe, effective, and people-centred traditional, complementary and integrative medicine (TCIM) constitutes a core objective of the World Health Organization (WHO) Traditional Medicine Strategy 2025–2034 and is an essential long-term aim of research in the field of ethnopharmacology. TCIM encompasses multiple healing systems practised alongside or in combination with modern conventional medicine. This includes *traditional medicine*, i.e., historically and culturally rooted health systems that pre-date modern conventional medicine and emphasise nature-based remedies and integrative, personalised care to restore balance between mind, body and environment; *complementary medicine*, formerly known as *complementary and alternative medicine*, which refers to health practices used alongside a country's conventional care to support health and wellness; and *integrative medicine*, an interdisciplinary, evidence-based approach combining traditional and/or complementary medical knowledge, skills and practices with conventional care (World Health Organization, 2025a).

Traditional medicine comprises diverse modalities, as exemplified by traditional Chinese medicine (TCM), which includes Chinese herbal medicine, acupuncture, moxibustion, cupping, tuina, taiji (tai chi), guasha and other specialised diagnostic and interventional technologies. Similarly, traditional Indian medicine, which encompasses a range of traditional practices, e.g., ayurveda, unani, siddha, naturopathy and yoga, and European traditional herbal medicines, also have substantial global reach and impact. Furthermore, there are numerous other regional and cultural traditions in Africa, America, Arabic and Middle-East countries, Australia, etc., which are less known globally but warrant further exploration.

TCIM has substantial global reach and influence. Approximately 80% countries officially recognise the use of acupuncture (World Health Organization, 2013), while an estimated 80% of the population in sub-Saharan Africa depends on traditional herbal medicine for primary healthcare (Kahumba et al., 2015). In China, TCM outpatient visits considerably rose, from 146 million in 2002 to 1.54 billion in 2023, with 99.6% of community clinics offering TCM services by 2023 (National Health Commission of the People's

Republic of China, 2003; 2024). Likewise, in the United States, reported adult use of TCIM rose from 19.2% in 2002 to 36.7% in 2022 (Nahin et al., 2024). In response to this growing prominence of TCIM, the new WHO Strategy outlines four key objectives: strengthening the evidence base, establishing robust regulation, acknowledging and integrating recognised practitioners and safe and effective practices/products into national health systems, and promoting cross-sectoral value and community empowerment (Burki, 2025; World Health Organization, 2025a). Achieving these goals requires rigorous research that not only respects relevant cultural contexts, but also is underpinned by international standards (IS), which are formal, often certifiable, established documents, developed and published by internationally recognised standards bodies through a process of consensus among its member countries, and international good practice guidelines (IGPG), which are recommended approaches or processes recognised as being superior to alternatives, representing the collective understanding and experience of a field (Von Schoen-Angerer et al., 2023).

In the intrinsically diverse and structurally complex field of TCIM, the use of preparations and metabolites derived from natural sources is common, constituting the main focus of this systematic review, which also covers other TCIM modalities, such as acupuncture and other physical medical interventions. Relevant IS/IGPG documents are produced by multiple international stakeholders and remain dispersed across numerous repositories. To address this fragmentation and improve accessibility, this scoping review was designed primarily to establish a unified repository by systematically mapping the global landscape of IS/IGPG development; a secondary aim was to compile TCIM- and IS/IGPG-related secondary documents, e.g., systematic reviews, perspectives and commentaries, as a proxy for IS/IGPG use and clinical evidence across the TCIM field.

2 Methods

2.1 Research design

This scoping review was conducted in line with the PRISMA-ScR guidelines (Tricco et al., 2018) and structured using an ICC

framework, encompassing three domains, *i.e.*, *Information*, *Concepts* and *Context*, as adapted from a reported PCC (*Population, Concept and Context*) framework (Chipps et al., 2025).

- Information: TCIM-related IS/IGPG.
- Concepts: Development and dissemination of IS/IGPG.
- Context: Progress, barriers, challenges and outlooks in IS/IGPG development and dissemination.

2.2 Search strategy

The strategies for systematic searches across five databases, PubMed, Web of Science, EMBASE, ProQuest, Cochrane Library (Supplementary Table S1) were supplemented by artificial intelligence (AI)-driven grey literature retrieval from the websites of relevant international organisations and industrial alliances (Supplementary Table S2), using a large language model (LLM), Claude Opus 4 (Anthropic, San Francisco, CA, United States). Data retrieved by LLM were extracted and reported following the TITAN Guidelines 2025 (Agha et al., 2025). To avoid artefacts brought about by LLM, all records were systematically evaluated manually against predefined exclusion and inclusion criteria and supplemented by invited experts from international organisations and relevant professional settings.

2.2.1 Inclusion criteria

- Documents relevant to TCIM (examples in Supplementary Table S3);
- Document type - standards, guidelines, benchmarks, frameworks, strategies or white papers;
- Publications on implementation, application, promotion, and enforcement of IS and IGPG;
- Secondary documents (e.g., systematic reviews, scoping reviews, meta-analyses, Cochrane library reports) relevant to clinical evidence of TCIM obtained from studies applying IS and IGPG;
- Date of publications (01/2000 to 04/2025); and
- No language restriction was applied.

2.2.2 Exclusion criteria

- Documents irrelevant to TCIM or IS/IGPG;
- Primary research studies or case reports; and
- Unfinished or draft documents, non-peer-reviewed preprints, and general news coverage.

2.3 Data extraction and analysis

At least two authors independently reviewed extracted data and assessed the quality of documents. Duplicates were removed manually and further supplemented by non-systematic searches and input by human experts. Any disagreements were resolved by consensus, yielding a fully authenticated corpus of documents with consistently high inter-rater agreement. The literature data were organised using Microsoft Excel and EndNote 21 (Clarivate, Philadelphia, PA, United States).

3 Results

3.1 Flowchart of literature screening

The data extraction process followed the PRISMA 2020 flowchart (Figure 1). Initial searches identified 22,544 records. After exclusion of 1,120 duplicates, eligibility assessment for full-text retrieval was conducted against predefined inclusion and exclusion criteria, which excluded withdrawn manuscripts, draft documents and general news coverage ($n = 20,689$). Through team deliberation and author consensus, 735 records were retained for analysis and supplemented by 1,291 non-systematic inputs by experts. A total of 2026 records were categorised as follows.


- Category (a) international standards and guidelines ($n = 1,624$, Supplementary Table S4) and
- Category (b) systematic reviews, perspectives and commentary documents ($n = 402$, cited in Supplementary Table S5).

3.2 IS/IGPG relevant to TCIM

Of the 1,624 records in Category (a) (Supplementary Table S4), including both IS ($n = 1,365$) and IGPG ($n = 259$), 22 were retrieved from the five bibliographic databases, with the remaining 1,602 sourced from online grey literature deposited at the websites of 33 international organisations and agencies, such as European Directorate for the Quality of Medicines and Healthcare (EDQM), Estados Unidos Mexicanos (EUM), African Union (AU), European Medicines Agency (EMA), International Organization for Standardization (ISO), the European Scientific Cooperative on Phytotherapy (ESCOP), the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), WHO, and the Enhancing the Quality and Transparency Of health Research (EQUATOR) Network (Figures 2A,B). These IS/IGPG were either broadly specific to TCIM, specific to a TCIM modality, or relevant but non-specific to TCIM (Figure 2C). The modalities of TCIM covered by IS/IGPG included acupuncture and moxibustion, herbal medicine, cupping, and some other complementary medical techniques derived from Chinese, Indian, Korean, Japanese or other medical traditions or relatively modern medical systems. These IS/IGPG were particularly focused on quality control and safety, education and terminology, reporting, harmonisation, AI, and economic evaluation (Figure 2D). Analysis of 5-year publication intervals over the past 25 years revealed a pronounced acceleration in IS/IGPG production in the past two decades, with outputs rising from 58 (2000–2005), 279 (2006–2010) and 279 (2011–2015) to 431 (2016–2020) and 562 (2021–2025) documents.

3.3 Analysis of TCIM- and IS/IGPG-related secondary documents

Among 402 records in Category (b), 215 were retrieved from PubMed, 78 from EMBASE, 27 from ProQuest and 77 from Cochrane, while five were retrieved from grey literature. All Web



of Science records were duplicates of those in PubMed and, therefore, excluded. These records included a total of 20,802 studies that involved TCIM and cited IS/IGPG, allowing for an analysis of TCIM modalities, IS/IGPG types, authorship and their countries, evidence levels and quality, both individually and collectively (Supplementary Table S5). The data also provided a cross-sectional overview of the disease spectrum in TCIM studies that applied or referred to IS/IGPG. When categorised according to the WHO International Classification of Diseases, 11th Revision (ICD-11), the analysis identified 103 specific diseases, a significant expansion from the 23 general disorder types noted in the pre-2002 period, as highlighted by the WHO Traditional Medicine Strategy 2002–2005 (World Health Organization, 2002a). These results yielded a glimpse of progress in the past two decades through a nuanced comparison (Supplementary Table S6).

4 Discussion

4.1 IS/IGPG for evidence-based TCIM

Over the past two decades, there has been a remarkable acceleration in the development of IGPG and IS (Figures 2A,B; Supplementary Table S4), including those specific to TCIM, to a particular TCIM modality, or important for, although not specific to, TCIM. Regarding TCIM modalities, the highest number of modality-specific IS/IGPG concern herbal medicine, acupuncture and moxibustion, homeopathy and

cupping, (Figure 2C), in keeping with the largest volumes of systematic review evidence for these modalities between 2018 and 2022, as documented by the WHO (World Health Organization, 2023b). The IS/IGPG compiled in this scoping review should be integrated with more general guidelines to ensure comprehensive, context-dependent coverage for both conventional medicine and TCIM. It's also important to recognise a dynamic nature of IS/IGPG. As any published IS/IGPG is likely to be regularly updated, it is essential to double-check and identify the most updated guidelines and TCIM-specific extensions while designing and reporting any work. For example, with the recent publication of the updated SPIRIT 2025 and CONSORT 2025 guidelines (Hopewell et al., 2025; Hróbjartsson et al., 2025), any randomised control trial protocols and reports in the field of TCIM should refer to these revised guidelines in addition to any updated specific guidelines. Just as this manuscript went into final production, the Second Edition of the African Herbal Pharmacopoeia was published. This volume consolidates scientific and ethnobotanical knowledge on 30 of the most significant medicinal plants in Africa (<https://www.routledge.com/African-Herbal-Pharmacopoeia/Katerere-Brendler-Feiter-Mahomoodally-Phillips/p/book/9780815374244>). As time progresses, we can expect further IS/IGPG publications to emerge in the coming years.

IS/IGPG are crucial for the modernisation of traditional medicine, an effort to bring ancient traditional practices into line with modern scientific standards (Xu et al., 2013). However, modernisation must not come at the expense of traditional medicine's core values, notably its integrative approach and its foundation in patients-centred,




FIGURE 2 Global landscape of the development and use of IS and IGPG in 2000–2025. **(A)** Proportions of contribution to the IGPG included in this study by international organisations and consortia. “Others”: databases, 20; CIOMS, 6; GIN, 5; IFOMPT, 5; PAHO, 3; SAR, 3; AAPB, 2; EUSOMA, 2; HRC, 2; WFCMS, 2; AOAC, 1; CA, 1; COPE, 1; DTx, 1; GA, 1; GHC, 1; HIMSS, 1; ICMJE, 1; LAP, 1; PROREUS, 1; TRAFFIC, 1. **(B)** Proportions of contribution to the IS included in this study by international organisations and consortia. **(C)** TCIM modalities covered by the included IS/IGPG; blue bars: IS/IGPG documents; green bars: TCIM- and IS/IGPG-related secondary documents. AAPB, Association for Applied Psychophysiology and Biofeedback; AOAC, Association of Official Agricultural Chemists International; AU, African Union; CA, Comunidad Andina (*La Comunidad Andina*); CIOMS, Council for International Organizations of Medical Sciences; COPE, Committee on Publication Ethics guidelines; DTx, Digital Therapeutics Alliance; EAEU, Eurasian Economic Union; EMA/HMPC, European Medicines Agency/Committee on Herbal Medicinal Products; EDQM, European Directorate for the Quality of Medicines and Healthcare; EQUATOR Network, Enhancing the QUALity and Transparency Of health Research; ESCOP, European Scientific Cooperative on Phytotherapy; EUM, Estados Unidos Mexicanos; EUSOMA, European Society of Breast Cancer Specialists; GA, Society for Medicinal Plant and Natural Product Research; GBIF, Global Biodiversity Information Facility; GCRSR, Global Coalition for Regulatory Science Research; GHC/GCC, The Gulf Health Council/ The Gulf Cooperation Council; GIN, Guidelines International Network; HIMSS, Healthcare Information and Management Systems Society; HL7 International, Health Level Seven International; HRC, The Pacific Health Research Committee and the Health Research Council of New Zealand; ICH, International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use; ICMJE, International Federation of Orthopaedic Manipulative Physical Therapist; IGPG, international good practice guidelines; IS, international standards; ISCMR, International Society for Complementary Medicine Research; (Continued)

FIGURE 2 (Continued)

ISE, International Society for Ethnopharmacology; ISO, International Organisation for Standardisation; LAP, Latin American Parliament; MMPT, manual and musculoskeletal physical therapies; NS: not specific, but nonetheless highly relevant, to TCIM; OMPT, orthopaedic manipulative physical therapies; PAHO, Pan American Health Organization; SAR, Society for Acupuncture Research; SIO, Society for Integrative Oncology; SIOP, International Society of Paediatric Oncology; TCIMg: General IS/IGPG in the broad field of traditional, complementary and integrative medicine, TCMg: General IS/IGPG in the field of traditional Chinese medicine; TRAFFIC, the long-term vision of the Kunming-Montreal Global Biodiversity Framework; WAHO, West African Health Organization; WFAS, World Federation of Acupuncture-moxibustion Societies; WFCMS, World Federation of Chinese Medicine Societies; WHO, World Health Organization.

personalised, syndrome-based differential diagnosis. Obviously, IS/IGPG should be applied and further refined with respect to these important concepts. For example, (i) TCIM's emphasis of patients-reported outcomes need to be acknowledged and included in clinical practice (Crossnohere et al., 2023) as well as in clinical trial design and reporting (Calvert et al., 2013); (ii) specific guidelines for N-of-1 clinical trials should address some of the personalised features of traditional medicine (Li et al., 2019); (iii) the traditional theories of "using different treatments for the same disease and the same treatment for different diseases" could be addressed by combining syndrome differentiation-based stratified diagnosis and Master Protocols, including Basket, Umbrella and Platform trials, which are guided by the CONSORT-ROUTINE guideline (Kwakkenbos et al., 2021); (iv) importantly, any modernised traditional medicines must be carefully studied in comparison with their corresponding traditional formulations to demonstrate any potential advantage in safety and efficacy, to clarify active components, and to ensure stable chemical profiles and activities through implementing Good Agricultural, Collection, and Manufacturing practices, rather than purely aim at commercial benefits; (v) to truly modernise, we must look beyond product regulation and include research, practitioners and practices, with the goal to harness traditional and complementary medicine for health promotion; and (vi) the integration of valid traditional practices into health systems would certainly be a key resource for reorienting care from a disease-focused to a person-centred model (Von Schoen-Angerer et al., 2023).

Finally, as most of the current IS/IGPG are consensus, rather than evidence-based, implementation science will be needed to examine whether they have achieved their goals in supporting the development of high-quality research evidence (Davidson et al., 2013) and to refine them in the light of new evidence.

4.2 International producers and depositories of IS/IGPG

We identified 33 producers and depositories, among which ICH, WHO, EQUATOR Network, WFAS and EMA were the leading producers of IGPG (Figure 2A), while EDQM, EUM, AU, EMA and ISO were leaders in publishing IS, particularly monographs of herbal drugs (Figure 2B). Although these international organisations collaborate periodically, their overall goals, tasks and statuses differ. Consequently, they publish complementary IS/IGPG, as exemplified by the WHO and the World Federation of Chinese Medicine Societies (WFCMS) jointly standardising TCM terminologies (World Health Organization, 2007d; World Federation of Acupuncture-Moxibustion Societies, 2008; World Health Organization, 2022b; Xu, 2023). The TCIM-related

extension guidelines deposited at the EQUATOR Network focus on reporting transparency and quality of clinical and experimental studies (Enhancing the QUALity and Transparency Of health Research), while WHO guidelines focus on global strategies, terminology, nomenclature, diagnosis, training benchmark and practice guidelines, including good manufacturing practices (GMP); ISO collaborated with WFCMS in publishing more than 100 standards of TCM products and has more recently started to develop Indian medicine-focused IS. Meanwhile, EMA, EDQM and ICH standards and guidelines are more of regulatory nature.

Focusing on European standards from the EMA, EDQM and ESCOP provides another excellent illustration of the division of labour between different standards bodies and guideline providers in the field of TCIM. Through the EMA, the European Union has established guidelines and directives for traditional and well-established herbal drugs and preparations, which are legally binding for marketing authorisation in 27 European countries. EMA monographs have already covered more than 160 herbal drugs, focusing on efficacy and safety. The EDQM, an institution of the European Council, oversees the elaboration and publication of monographs for the European Pharmacopoeia (Ph. Eur.), which is legally binding in its 41 member states. It contains the quality standards of 346 herbal drugs and herbal drug preparations, plus 8 general guidelines and 41 individual monographs defining the quality of homoeopathic preparations (European Pharmacopoeia, 2022). Since 2015, the Eurasian Economic Union (EAEU) has been established to develop an integrated single market. The EAEU has passed directives to harmonise herbal quality standards (Eurasian Economic Union, 2016a; Eurasian Economic Union, 2016b; Eurasian Economic Union, 2018a; Eurasian Economic Union, 2018b; Eurasian Economic Union, 2018c; Eurasian Economic Union, 2019a; Eurasian Economic Union, 2019b; Eurasian Economic Union, 2019c; Eurasian Economic Union, 2021a; Eurasian Economic Union, 2021b; Eurasian Economic Union, 2022) and national pharmacopoeias (Eurasian Economic Union, 2020) among member states, including Armenia, Belarus, Kazakhstan, Kyrgyzstan and Russia (Whaley et al., 2023; Frolova et al., 2024; Olenina, 2025). In contrast to these regulatory bodies, the ESCOP is an umbrella organisation representing national herbal medicine or phytotherapy societies across Europe. It has so far published 85 monographs, which review the therapeutic use and scientific evidence of herbal drugs used in European phytotherapy (The European Scientific Cooperative on Phytotherapy, 2003; The European Scientific Cooperative on Phytotherapy, 2009) (Figures 2A,B). Though not legally binding, these monographs are important guidelines for clinical use and scientific research.

To sustain quality, it is essential that the most updated IS/IGPG are accessed from the websites of the relevant IS/IGPG producers

(Figures 2A, 2B; Suppl. Table 4) (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2000a; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2000b; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2000c; World Health Organization, 2000a; World Health Organization, 2000b; Macpherson et al., 2001; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2002; World Health Organization, 2002b; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2003a; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2003b; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2003c; World Health Organization, 2003a; World Health Organization, 2003b; World Health Organization, 2003c; World Health Organization, 2003d; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2004a; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2004b; World Health Organization, 2004a; World Health Organization, 2004b; European Medicines Agency, 2005; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2005a; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2005b; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2005c; Liu et al., 2005; European Medicines Agency, 2006a; European Medicines Agency, 2006b; Gagnier et al., 2006; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2006a; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2006b; Cassileth et al., 2007; Dean et al., 2007; Deng et al., 2007; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2007a; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2007b; Von Elm et al., 2007; World Health Organization, 2007a; World Health Organization, 2007b; World Health Organization, 2007c; European Medicines Agency, 2008a; European Medicines Agency, 2008b; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2008a; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2008b; World Health Organization, 2008; Deng et al., 2009; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2009a; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2009b; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2009c; Kelly et al., 2009; World Health Organization, 2009; European Medicines Agency, 2010a; European Medicines Agency, 2010b; European Medicines Agency, 2010c; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2010a; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2010b; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2010c; International Council for Harmonization of Technical

Requirements for Pharmaceuticals for Human Use, 2010d; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2010e; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2010f; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2010g; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2010h; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2010i; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2010j; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2010k; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2010l; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2010m; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2010n; Macpherson et al., 2010; Moher et al., 2010; Balshem et al., 2011; Bian and Chang, 2011; European Medicines Agency, 2011; Guyatt, G. et al., 2011; Guyatt, G. H. et al., 2011; World Health Organization, 2011a; World Health Organization, 2011b; Society for Acupuncture Research, 2011-2016; Council for International Organizations of Medical Sciences, 2012; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2012a; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2012b; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2012c; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2012d; International Federation of Orthopaedic Manipulative Physical Therapists, 2012; Qaseem et al., 2012; Welch et al., 2012; World Health Organization, 2012a; World Health Organization, 2012b; Beller et al., 2013; Chan et al., 2013; Cheng et al., 2013; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2013; Council for International Organizations of Medical Sciences, 2014; Greenlee et al., 2014; International Organization for Standardization, 2014a; International Organization for Standardization, 2014b; International Organization for Standardization, 2014c; International Organization for Standardization, 2014d; Munk and Boulanger, 2014; Witt et al., 2014; Danan and Teschke, 2015; Hutton et al., 2015; International Organization for Standardization, 2015a; International Organization for Standardization, 2015b; International Organization for Standardization, 2015c; International Organization for Standardization, 2015d; Moher et al., 2015; Stewart et al., 2015; Council for International Organizations of Medical Sciences, 2016a; Council for International Organizations of Medical Sciences, 2016b; European Medicines Agency, 2016a; European Medicines Agency, 2016b; Heidari et al., 2016; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2016; International Federation of Orthopaedic Manipulative Physical Therapists, 2016a; International Federation of Orthopaedic Manipulative Physical Therapists, 2016b; International Organization for Standardization, 2016a; International Organization for Standardization, 2016b; International Organization for Standardization, 2016c; International Organization for Standardization, 2016d; Lachar

et al., 2016; Ogrinc et al., 2016; World Health Organization, 2016a; World Health Organization, 2016b; Zorzela et al., 2016; Biganzoli et al., 2017; Chen, Y. et al., 2017a; Chen, Yaolong et al., 2017b; Cheng et al., 2017; European Medicines Agency, 2017; Greenlee et al., 2017; Guise et al., 2017; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2017a; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2017b; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2017c; International Federation of Orthopaedic Manipulative Physical Therapists, 2017; International Organization for Standardization, 2017a; International Organization for Standardization, 2017b; International Organization for Standardization, 2017c; International Organization for Standardization, 2017d; International Organization for Standardization, 2017e; International Organization for Standardization, 2017f; International Organization for Standardization, 2017g; International Organization for Standardization, 2017h; International Organization for Standardization, 2017i; International Organization for Standardization, 2017j; International Organization for Standardization, 2017k; International Organization for Standardization, 2017l; International Organization for Standardization, 2017m; International Organization for Standardization, 2017n; International Organization for Standardization, 2017o; International Organization for Standardization, 2017p; International Organization for Standardization, 2017q; Chen et al., 2017a; World Health Organization, 2017; World Health Organization, 2023; Committee on Publication Ethics Guidelines, 2018; Heinrich et al., 2018; International Organization for Standardization, 2018a; International Organization for Standardization, 2018b; International Organization for Standardization, 2018c; International Organization for Standardization, 2018d; International Organization for Standardization, 2018e; International Organization for Standardization, 2018f; International Organization for Standardization, 2018g; International Organization for Standardization, 2018h; International Organization for Standardization, 2018i; World Health Organization, 2018a; World Health Organization, 2018b; Dai et al., 2019; European Medicines Agency, 2019; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2019a; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2019b; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2019c; International Organization for Standardization, 2019a; International Organization for Standardization, 2019b; International Organization for Standardization, 2019c; International Organization for Standardization, 2019d; International Organization for Standardization, 2019e; International Organization for Standardization, 2019f; International Organization for Standardization, 2019g; International Organization for Standardization, 2019h; International Organization for Standardization, 2019i; International Organization for Standardization, 2019j; International Organization for Standardization, 2019k; International Organization for Standardization, 2019l; International Organization for Standardization, 2019m; International Organization for Standardization, 2019n; International Organization for Standardization, 2019o; International Organization for Standardization, 2019p; International Organization for Standardization, 2019q; International Organization for Standardization, 2019r; Tang et al., 2019; Wang et al., 2019; World Health Organization, 2019a; World Health Organization, 2019b; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2020; International Organization for Standardization, 2020a; International Organization for Standardization, 2020b; International Organization for Standardization, 2020c; International Organization for Standardization, 2020d; International Organization for Standardization, 2020e; International Organization for Standardization, 2020f; International Organization for Standardization, 2020g; International Organization for Standardization, 2020h; International Organization for Standardization, 2020i; International Organization for Standardization, 2020j; International Organization for Standardization, 2020k; International Organization for Standardization, 2020l; International Organization for Standardization, 2020m; International Organization for Standardization, 2020n; International Organization for Standardization, 2020o; International Organization for Standardization, 2020p; International Organization for Standardization, 2020q; International Organization for Standardization, 2020r; International Organization for Standardization, 2020s; International Organization for Standardization, 2020t; International Organization for Standardization, 2020u; McGowan et al., 2020; Percie Du Sert et al., 2020; Society for Integrative Oncology, 2020; World Health Organization, 2020a; World Health Organization, 2020b; World Health Organization, 2020c; Xie et al., 2020; Zhang et al., 2020a; Zhang et al., 2020b; Zhang et al., 2020c; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2021; International Organization for Standardization, 2021a; International Organization for Standardization, 2021b; International Organization for Standardization, 2021c; International Organization for Standardization, 2021d; International Organization for Standardization, 2021e; International Organization for Standardization, 2021f; International Organization for Standardization, 2021g; International Organization for Standardization, 2021h; International Organization for Standardization, 2021i; International Organization for Standardization, 2021j; International Organization for Standardization, 2021k; International Organization for Standardization, 2021l; International Organization for Standardization, 2021m; Page et al., 2021; Rethlefsen et al., 2021; Tang et al., 2021; Council for International Organizations of Medical Sciences, 2022; European Medicines Agency, 2022a; European Medicines Agency, 2022b; European Medicines Agency, 2022c; Husereau et al., 2022; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2022a; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2022b; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2022c; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2022d; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2022e; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2022f; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2022g; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2022h;

International Organization for Standardization, 2022i; International Organization for Standardization, 2022j; International Organization for Standardization, 2022k; International Organization for Standardization, 2022l; International Organization for Standardization, 2022m; International Organization for Standardization, 2022n; International Organization for Standardization, 2022o; International Organization for Standardization, 2022p; International Organization for Standardization, 2022q; International Organization for Standardization, 2022r; International Organization for Standardization, 2022s; International Organization for Standardization, 2022t; International Organization for Standardization, 2022u; Mao et al., 2022a; Mao et al., 2022b; Song et al., 2022; Ward et al., 2022; World Health Organization, 2022a; Association for Applied Psychophysiology and Biofeedback, 2023; Carlson et al., 2023; Christensen et al., 2023; Crossnohere et al., 2023; Digital Therapeutics Alliance, 2023; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2023a; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2023b; International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 2023c; International Organization for Standardization, 2023a; International Organization for Standardization, 2023b; International Organization for Standardization, 2023c; International Organization for Standardization, 2023d; International Organization for Standardization, 2023e; International Organization for Standardization, 2023f; International Organization for Standardization, 2023g; International Organization for Standardization, 2023h; International Organization for Standardization, 2023i; International Organization for Standardization, 2023j; International Organization for Standardization, 2023k; Ma et al., 2023; The Wildlife Trade Monitoring Network, 2023; World Federation of Acupuncture-Moxibustion Societies, 2023a; World Federation of Acupuncture-Moxibustion Societies, 2023b; World Federation of Acupuncture-Moxibustion Societies, 2023c; World Federation of Acupuncture-Moxibustion Societies, 2023d; World Federation of Acupuncture-Moxibustion Societies, 2023e; World Federation of Acupuncture-Moxibustion Societies, 2023f; World Federation of Acupuncture-Moxibustion Societies, 2023g; World Federation of Acupuncture-Moxibustion Societies, 2023h; World Federation of Acupuncture-Moxibustion Societies, 2023i; World Federation of Acupuncture-Moxibustion Societies, 2023j; World Federation of Acupuncture-Moxibustion Societies, 2023k; World Federation of Acupuncture-Moxibustion Societies, 2023l; World Federation of Acupuncture-Moxibustion Societies, 2023m; World Federation of Acupuncture-Moxibustion Societies, 2023n; World Federation of Acupuncture-Moxibustion Societies, 2023o; World Federation of Acupuncture-Moxibustion Societies, 2023p; World Federation of Acupuncture-Moxibustion Societies, 2023q; World Federation of Acupuncture-Moxibustion Societies, 2023r; World Federation of Acupuncture-Moxibustion Societies, 2023s; World Federation of Acupuncture-Moxibustion Societies, 2023t; World Federation of Acupuncture-Moxibustion Societies, 2023u; World Federation of Acupuncture-Moxibustion Societies, 2023v; World Federation of Acupuncture-Moxibustion Societies, 2023w; World Federation of Acupuncture-Moxibustion Societies, 2023x; World Federation of Acupuncture-Moxibustion Societies, 2023y; World Federation of Acupuncture-Moxibustion Societies, 2023z; World Federation of Acupuncture-Moxibustion Societies, 2024a; World Federation of Acupuncture-Moxibustion Societies, 2024b; World Federation of Acupuncture-Moxibustion Societies, 2024c; World Federation of Acupuncture-Moxibustion Societies, 2024d; World Federation of Acupuncture-Moxibustion Societies, 2024e; World Federation of Acupuncture-Moxibustion Societies, 2024f; World Federation of Acupuncture-Moxibustion Societies, 2024g; World Federation of Acupuncture-Moxibustion Societies, 2024h; World Federation of Acupuncture-Moxibustion Societies, 2024i; World Federation of Acupuncture-Moxibustion Societies, 2024j; World Federation of Acupuncture-Moxibustion Societies, 2024k; World Federation of Acupuncture-Moxibustion Societies, 2024l; World Federation of Acupuncture-Moxibustion Societies, 2024m; World Federation of Acupuncture-Moxibustion Societies, 2024n; World Federation of Acupuncture-Moxibustion Societies, 2024o; World Federation of Acupuncture-Moxibustion Societies, 2024p; World Federation of Acupuncture-Moxibustion Societies, 2024q; Li et al., 2024; Rubio et al., 2024; World Federation of Acupuncture-Moxibustion Societies, 2024; World Health Organization, 2024a; World Health Organization, 2024b; World Health Organization, 2024c; International Committee of Medical Journal Editors, 2025; International Organization for Standardization, 2025a; International Organization for Standardization, 2025b; International Organization for Standardization, 2025c; International Organization for Standardization, 2025d; Schünemann et al., 2025; Sousa-Pinto et al., 2025; Guidelines International Network, NA; International Organization for Standardization, NA; Society for Acupuncture Research, NA; World Health Organization, 2026a; World Health Organization, 2026b; World Health Organization, 2026c; World Health Organization, 2026d; World Health Organization, 2026e; World Health Organization, 2026f) (European Pharmacopoeia, 2022; The Gulf Health Council, 2022; European Medicines Agency, 2004).

To date, IS/IGPG have only been developed for a limited number of TCIM modalities (Figure 2C). Future efforts are expected to expand TCIM coverage to a wider range of therapies, whenever feasible. While wider stakeholder participation is crucial for such extensions, the WHO emphasises the need for safeguards that respect indigenous rights and protect traditional knowledge from misappropriation, which remains an unresolved challenge (Burki, 2025). Looking forward, WHO will need to enhance coordination among its member states to encourage consistency in allocating available resources for research on TCIM; indeed, many countries still fail to adequately invest in TCIM research, which prevents the generation of evidence relevant at the local level and limits integration of traditional medicines into national health systems (Von Schoen-Angerer et al., 2023). Additionally, applying mainstream clinical research standards, which are often cost-prohibitive and structurally misaligned with TCIM paradigms, may not be appropriate for authentic TCIM practice. Indeed,

effective models for integrating traditional medicine into healthcare systems are often built upon a foundation of established traditional use, even in the absence of robust RCTs. This is evident in the recognition of Ayurveda in India, TCM in China, and the registration scheme for traditional herbal medicines in Europe. These nuances of traditional medicine integration are worthy of consideration, indicating the need for specialised IS/IGPG tailored to TCIM to respect their conceptual diversity, traditional use histories, and holistic approaches, while guaranteeing quality, safety and cost-effectiveness.

4.3 IS/IGPG users and usage

Despite the complexity of TCIM, its combination with new technologies, such as omics (Chen et al., 2024) or AI (Wang et al., 2025; World Health Organization, 2025b), brings about many promising opportunities. Beyond recurring issues with botanical and pharmacopoeial nomenclature and quality (Rivera et al., 2014; Heinrich et al., 2022; Wang et al., 2023), a lack of adherence to existing IS/IGPG commonly results in low-quality and biased research data (Supplementary Table S5). The accessibility to existing IS/IGPG can be a major obstacle. Many documents exist in the form of unindexed grey literature, requiring considerable effort, multilingual skills, and information literacy to retrieve. Cost disparities also hinder access: while WHO and some organisations provide free resources, ISO and other bodies charge fees, creating difficulties for low-income regions, organisations and individuals that cannot afford the costs of up-to-date standards.

The value of IS/IGPG can only be fully appreciated by considering their implementation at multiple levels: in basic sciences, medical research, and therapy. It requires adaptation of science and health policies and their effective auditing, as well as effective use by researchers and practitioners. Therefore, a global disparity that appears in the use of these tools, dominated by leading economies, is a cause for concern (Supplementary Table S5). Given the importance of TCIM in the developing world, this lack of use of existing IS/IGPG in this major part of the world calls for urgent attention. Overcoming language barriers may also be crucial. Of note, the EQUATOR Network makes a step in that direction; however, as of 5 October 2025, only a small proportion of its guidelines (688) have been translated into 17 languages. For example, only 25 guidelines have official translations in Chinese (Equator Network, NA). More official translations and dissemination activities should increase awareness, endorsement and implementation.

There are many approaches to promoting the dissemination and implementation of IS/IGPG in the field of TCIM, for which Hong Kong's methodologies for policy guidance may offer valuable inspiration. These include (i) applying the CIFR framework to identify barriers and facilitators for improving guidance uptake (Damschroder et al., 2009); (ii) utilising the RE-AIM framework to enhance dissemination, outreach and implementation (Glasgow et al., 1999; Lam et al., 2022); and (iii) developing focus groups and Delphi surveys to inform policies (Lam et al., 2022).

At the 78th World Health Assembly on 27 May 2025, the WHO has made it a priority to strengthen national capacities in evidence-

based decision-making for the adoption and effective application of norms and standards. It can then be expected that the WHO is to play a leading role in a proactive global dissemination of IS/IGPG. Governmental agencies, charitable funding bodies, healthcare associations, international societies, like the GP-TCM Research Association (<https://www.gp-tcm.org/>), and individual scholars all have a role to play.

4.4 Limitations

This search using English keywords and MeSH terms was limited to publications between 2000 and 2025, which precludes the coverage of more classic IS and IGPG, e.g., the WHO guidelines on quality, safety, efficacy, research, rational use and conservation of medicinal plants published before 2000 (World Health Organization, 1991). Searches were also limited by the availability of grey literature on organisational websites, meaning omissions may have occurred despite combining this with systematic searches of five databases, AI-assisted systematic retrieval and human expert input. Through expert input, IS/IGPG publications in non-English languages were included, e.g., (i) more than 20 WFCMS guidelines on TCM prescription, dispensing, delivery, decoction and administration, which are published in Chinese with or without an English title (World Federation of Chinese Medicine Societies, 2022-2026); and (ii) the Spanish-language Mexican herbal pharmacopoeia, that is binding for several Latin American countries (Estados Unidos Mexicanos, 2021a; Estados Unidos Mexicanos, 2021b). Nonetheless, our team lacked experts from the Americas, Southern parts of Africa, as well as Middle Eastern, Oceanic, and ASEAN countries, which may have limited the intended worldwide coverage, especially as it relates to non-English documents and grey literature. Although this scoping review focuses on international standards and guidelines, it does not imply that national or regional guidelines are not important. In fact, many regulatory standards and practice guidelines are not yet harmonised internationally. In such contexts, national and regional standards and guidelines should be considered, observed and fully respected. Furthermore, we cannot exclude the possibility that the Category (b) dataset across the 14,999 studies listed in Supplementary Table S5 may involve overlapping data, as previously reported by Rizzo et al (Rizzo et al., 2025). Finally, as with any scoping review, a major limitation is the lack of formal assessment of the quality and impact of included documents. Both of these factors are crucial and should be addressed in future studies.

5 Conclusion

This scoping review has mapped the development of IS/IGPG within the TCIM field and created a comprehensive, accessible repository, thereby fulfilling its primary objectives. It has also compiled a database of secondary documents at the intersection of TCIM and IS/IGPG to inform future work, which includes raising awareness, promoting endorsement, implementation and harmonisation of IS/IGPG, as well as evaluating the effectiveness of these standards and guidelines in supporting evidence-based TCIM worldwide.

Author contributions

XW: Software, Investigation, Data curation, Resources, Methodology, Visualization, Writing – original draft, Project administration, Funding acquisition, Conceptualization, Validation, Writing – review and editing, Supervision, Formal Analysis. HL: Resources, Validation, Formal Analysis, Methodology, Funding acquisition, Writing – review and editing, Investigation. SJ: Writing – original draft, Software, Formal Analysis, Resources, Methodology, Investigation. NY: Writing – original draft, Software, Formal Analysis, Resources, Methodology, Investigation, Visualization. DW: Methodology, Formal Analysis, Software, Data curation, Resources, Writing – review and editing, Investigation. HX: Writing – review and editing. NR: Writing – review and editing. L-FS: Writing – review and editing. MH: Writing – review and editing. MW: Writing – review and editing. MS: Writing – review and editing. LZ: Writing – review and editing. FB: Writing – review and editing. TE: Writing – review and editing. SBA: Writing – review and editing. CB-SL: Writing – review and editing. WW: Writing – review and editing. RB: Data curation, Project administration, Validation, Methodology, Writing – review and editing, Supervision, Resources, Investigation, Formal Analysis. PD: Project administration, Validation, Resources, Conceptualization, Data curation, Visualization, Methodology, Formal Analysis, Investigation, Writing – review and editing, Supervision, Funding acquisition, Writing – original draft, Software. QX: Investigation, Data curation, Validation, Conceptualization, Funding acquisition, Supervision, Methodology, Formal Analysis, Project administration, Resources, Writing – review and editing, Writing – original draft, Software.

Funding

The author(s) declared that financial support was received for this work and/or its publication. The study was financially supported by the National Natural Science Foundation of China (82274155, XW); The Key Project of Department of Science and Technology of Hubei Province (2025CSA097, XW); The Key Project of Hubei Bureau of Traditional Chinese Medicine (ZY2025Z019, XW); the Open Project of Hubei Key Laboratory of Wudang Local Chinese Medicine Research (Hubei University of Medicine) (WDCM2024032, HL), as well as Kidney Research UK (RP38/2014, QX) and the PKD Charity (ARPKD-19-02, QX). This research was carried out as part of the Wallonie-Bruxelles international project 2-2, “Amélioration de la qualité et de la sécurité des produits de médecine traditionnelle vendus sur les marchés des trois villes principales de la RDC—TRADIQUAL” and of the ARES projects “Reconnaissance mutuelle des savoirs traditionnels et modernes: conditions pour l’implémentation durable d’une médecine intégrative dans le contexte malgache (TradiMad)” and “Valorization of the medicinal and agroecological potential of natural extracts in Northern Vietnam

(MEDNATHAN)”. The funders played no role in this study, which is the sole responsibility of the authors.

Acknowledgements

We are most grateful to Oche Barnabas Esa (Department of Natural Medicine, Green Centre Academy of Natural Medicine, Lagos, Nigeria) for sharing the information about the herbal monographs in the West African Herbal Pharmacopoeia, and to Alexander Shikov (Saint-Petersburg State Chemical Pharmaceutical University) for sharing the relevant EAEU literature. We thank kt Friar, the WHO, for technical support.

Conflict of interest

Author MW was employed by SU BioMedicine B.V.

The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors CB-SL, L-FS, LZ, HX, MH, MS, RB, TE, MS declared that they were an editorial board member of *Frontiers* at the time of submission. This had no impact on the peer review process and the final decision.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by *Frontiers* with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2026.1742400/full#supplementary-material>

References

- Agha, R. A., Mathew, G., Rashid, R., Kerwan, A., Al-Jabir, A., Sohrabi, C., et al. (2025). Transparency in the reporting of artificial intelligence – the TITAN guideline. *Prem. J. Sci.* 10, 100082. doi:10.70389/PJS.100082
- Akl, E. A., Khabba, J., Iannizzi, C., Piechotta, V., Kahale, L. A., Barker, J. M., et al. (2024). Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. *BMJ* 387, e079183. doi:10.1136/bmj-2024-079183
- Association for Applied Psychophysiology and Biofeedback (2023). Evidence-based practice in Biofeedback and neurofeedback 4th ed. Available online at: <https://aapb.org/Publications> (Accessed August 10, 2025).
- Association of Official Agricultural Chemists International (2024). AOAC INTERNATIONAL guidelines for laboratories performing microbiological and chemical analyses of food, dietary supplements, pharmaceuticals, and cannabis. Available online at: <https://www.aoac.org/aoac-accreditation-guidelines-for-laboratories-alacc/> (Accessed October 13, 2025).
- Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., et al. (2011). GRADE guidelines: 3. Rating the quality of evidence. *J. Clin. Epidemiol.* 64 (4), 401–406. doi:10.1016/j.jclinepi.2010.07.015
- Beller, E. M., Glasziou, P. P., Altman, D. G., Hopewell, S., Bastian, H., Chalmers, I., et al. (2013). PRISMA for abstracts: reporting systematic reviews in journal and conference abstracts. *PLoS Med.* 10 (4), e1001419. doi:10.1371/journal.pmed.1001419
- Bian, Z. X., and Chang, Y. H. (2011). Revised STRICTA as an extension of the CONSORT statement: more items should be involved in the checklist. *J. Altern. Complement. Med.* 17 (2), 97–98. doi:10.1089/acm.2010.0353
- Biganzoli, L., Marotti, L., Hart, C. D., Cataliotti, L., Cutuli, B., Kühn, T., et al. (2017). Quality indicators in breast cancer care: an update from the EUSOMA working group. *Eur. J. Cancer* 86, 59–81. doi:10.1016/j.ejca.2017.08.017
- Bower, J. E., Lacchetti, C., Alici, Y., Barton, D. L., Bruner, D., Canin, B. E., et al. (2024). Management of fatigue in adult survivors of cancer: ASCO–society for integrative oncology guideline update. *J. Clin. Oncol.* 42 (20), 2456–2487. doi:10.1200/jco.24.00541
- Burki, T. (2025). WHO adopts new strategy on traditional medicine. *Lancet* 405 (10493), 1897–1898. doi:10.1016/s0140-6736(25)01142-0
- Calvert, M., Blazeby, J., Altman, D. G., Revicki, D. A., Moher, D., Brundage, M. D., et al. (2013). Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. *JAMA* 309 (8), 814–822. doi:10.1001/jama.2013.879
- Carlson, L. E., Ismaila, N., Addington, E. L., Asher, G. N., Atreya, C., Balneaves, L. G., et al. (2023). Integrative oncology care of symptoms of anxiety and depression in adults with cancer: society for integrative oncology–ASCO guideline. *J. Clin. Oncol.* 41 (28), 4562–4591. doi:10.1200/jco.23.00857
- Carlson, L. E., Tripathy, D., Zick, S. M., Balneaves, L. G., Lee, R. T., and Greenlee, H. (2024). The Society for Integrative Oncology–American Society of Clinical Oncology Joint guidelines on integrative therapies for symptom management–overview and key recommendations. *J. Integr. Complement. Med.* 30 (7), 596–601. doi:10.1089/jicm.2024.0452
- Cassileth, B. R., Deng, G. E., Gomez, J. E., Johnstone, P. A. S., Kumar, N., Vickers, A. J., et al. (2007). Complementary therapies and integrative oncology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest* 132 (3), 340S–354S. doi:10.1378/chest.07.1389
- Chan, A. W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Kraljević, K., et al. (2013). SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann. Intern. Med.* 158 (3), 200–207. doi:10.7326/0003-4819-158-3-201302050-00583
- Chen, Y., Yang, K., Marušić, A., Qaseem, A., Meerpohl, J. J., Flottorp, S., et al. (2017a). A reporting tool for practice guidelines in health care: the RIGHT statement. *Ann. Intern. Med.* 166 (2), 128–132. doi:10.7326/m16-1565
- Chen, Y., Yang, K., Marušić, A., Qaseem, A., Meerpohl, J. J., Flottorp, S., et al. (2017b). RIGHT Explanation and Elaboration: guidance for reporting practice guidelines. Available online at: <https://cdn.amegroups.cn/static/application/fa8c4ed9db385e2643c0a76581a82fbb/fa8c4ed9db385e2643c0a76581a82fbb.pdf> (Accessed August 27, 2025).
- Chen, L., Yang, T., Wu, J., Cheng, G., Zhao, M., Zhou, Y., et al. (2024). Multi-omics strategy reveals that cordyceps sinensis ameliorates sepsis-associated acute kidney injury via reprogramming of mitochondrial energy metabolism and macrophage polarization. *Acta Mater. Medica* 3 (3), 269–288. doi:10.15212/AMM-2024-0018
- Cheng, C. W., Fu, S. F., Zhou, Q. H., Wu, T. X., Shang, H. C., Tang, X. D., et al. (2013). Extending the CONSORT statement to moxibustion. *J. Integr. Med.* 11 (1), 54–63. doi:10.3736/jintegrated2013009
- Cheng, C. W., Wu, T. X., Shang, H. C., Li, Y. P., Altman, D. G., Moher, D., et al. (2017). CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration (traditional Chinese version). *Ann. Intern. Med.* 167 (2), W7–w20. doi:10.7326/IsTranslatedFrom_M17-2977_1
- Chippis, J., Sibindi, T., Cromhout, A., and Bagula, A. (2025). Use of artificial intelligence in healthcare in South Africa: a scoping review. *Health SA* 30, 2977. doi:10.4102/hsag.v30i0.2977
- Christensen, R. E., Yi, M. D., Kang, B. Y., Ibrahim, S. A., Anver, N., Dirr, M., et al. (2023). Development of an international glossary for clinical guidelines collaboration. *J. Clin. Epidemiol.* 158, 84–91. doi:10.1016/j.jclinepi.2023.03.026
- Committee on Publication Ethics guidelines. (2018). Best practices for preprints. doi:10.24318/R4WByao2
- Council for International Organizations of Medical Sciences (2012). International guiding principles for biomedical research involving animals. Available online at: <https://cioms.ch/publications/product/international-guiding-principles-for-biomedical-research-involving-animals-2/> (Accessed October 13, 2025).
- Council for International Organizations of Medical Sciences (2014). Practical approaches to risk minimisation for medicinal products: report of CIOMS working group IX. Available online at: <https://cioms.ch/publications/product/practical-approaches-to-risk-minimisation-for-medicinal-products-report-of-cioms-working-group-ix/> (Accessed October 13, 2025).
- Council for International Organizations of Medical Sciences. (2016a). 2016 International ethical guidelines for health-related research involving humans. doi:10.56759/rxgl7405
- Council for International Organizations of Medical Sciences. (2016b). International guidelines on good governance practice for research institutions. doi:10.56759/hslk3269
- Council for International Organizations of Medical Sciences. (2022). Patient involvement in the development, regulation and safe use of medicines. doi:10.56759/iew8982
- Crossnohere, N. L., Brundage, M., Snyder, C., and Group, t. A. (2023). The PROTEUS Guide to implementing patient-reported outcomes in clinical practice: a synthesis of resources. Available online at: <https://theptecconsortium.org/wp-content/uploads/2023/04/PROTEUS-Practice-Guide.pdf> (Accessed August 28, 2025).
- Dai, L., Cheng, C.-w., Tian, R., Zhong, L. L. D., Li, Y.-p., Lyu, A.-p., et al. (2019). Standard protocol items for clinical trials with traditional Chinese medicine 2018: recommendations, explanation and elaboration (SPIRIT-TCM extension 2018). *Chin. J. Integr. Med.* 25 (1), 71–79. doi:10.1007/s11655-018-2999-x
- Damschroder, L. J., Aron, D. C., Keith, R. E., Kirsh, S. R., Alexander, J. A., and Lowery, J. C. (2009). Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. *Implement Sci.* 4, 50. doi:10.1186/1748-5908-4-50
- Danan, G., and Teschke, R. (2015). RUCAM in drug and herb induced liver injury: the update. *Int. J. Mol. Sci.* 17 (1). doi:10.3390/ijms17010014
- Davidson, E., Vlachojannis, J., Cameron, M., and Chrubasik, S. (2013). Best available evidence in cochrane reviews on herbal medicine? *Evid. Based Complement. Altern. Med.* 2013, 163412. doi:10.1155/2013/163412
- Dean, M. E., Coulter, M. K., Fisher, P., Jobst, K. A., and Walach, H. (2007). Reporting data on homeopathic treatments (RedHot): a supplement to CONSORT. *J. Altern. Complement. Med.* 13 (1), 19–23. doi:10.1089/acm.2006.6352
- Deng, G. E., Cassileth, B. R., Cohen, L., Gubili, J., Johnstone, P. A., Kumar, N., et al. (2007). Integrative oncology practice guidelines. *J. Soc. Integr. Oncol.* 5 (2), 65–84.
- Deng, G. E., Frenkel, M., Cohen, L., Cassileth, B. R., Abrams, D. I., Capodice, J. L., et al. (2009). Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. *J. Soc. Integr. Oncol.* 7 (3), 85–120.
- Digital Therapeutics Alliance (2023). Policy maker and Payor DTx evaluation toolkit. Available online at: <https://dtxalliance.org/understanding-dtx/dtx-evaluation-toolkit/> (Accessed October 12, 2025).
- Enhancing the QUALITY and Transparency Of health Research (NA). Hong Kong, China: The Chinese EQUATOR Centre. Available online at: <https://www.equator-network.org/about-us/chinese-equator-centre/> (Accessed April 13, 2025).
- EQUATOR Network (NA). Translations of reporting guidelines. Available online at: <https://www.equator-network.org/library/translations-of-reporting-guidelines/#Chinese> (Accessed April 13, 2025).
- Estados Unidos Mexicanos (2021a). Farmacopea herbolaria. Available online at: <https://www.farmacopea.org.mx/Repositorio/Preguntas/Demo%20FHEUM.pdf> (Accessed October 28, 2025).
- Estados Unidos Mexicanos (2021b). Farmacopea homeopática. Available online at: <https://farmacopea.org.mx/publicaciones-detalle.php?m=3&pid=15> (Accessed October 28, 2025).
- Eurasian Economic Union (2016a). Rules for registration and examination of safety, quality and efficacy of medical products. Available online at: https://eec.eaeunion.org/upload/medialibrary/6cd/2-Decision-46-Feb-12--2016_Rules-for-Registration-and-Examination-of-MP.docx (Accessed December 12, 2025).
- Eurasian Economic Union (2016b). Rules of proper production practice of the Eurasian Economic Union. Available online at: <https://cis-legislation.com/document.fwx?rgn=93251> (Accessed December 12, 2025).
- Eurasian Economic Union (2018a). Rules of proper practice of cultivation, collection, processing and storage of initial raw materials of plant origin. Available online at: <https://cis-legislation.com/document.fwx?rgn=104616#A5580GXWHV> (Accessed December 12, 2025).

- Eurasian Economic Union (2018b). О Руководстве По качеству лекарственных растительных Препаратов [Guidelines for the quality of herbal medicinal products]. Available online at: https://www.consultant.ru/document/cons_doc_LAW_297889/eb6e97c2140d968b8d1581a5effa671f74d9747d/ (Accessed December 12, 2025).
- Eurasian Economic Union (2018c). Об утверждении Правил надлежащей Практики выращивания, сбора, обработки и хранения исходного сырья растительноГО Происхождения [rules for good practice in growing, harvesting, processing and storage of raw materials of plant origin]. Available online at: https://www.consultant.ru/document/cons_doc_LAW_291919/92d3e3d03094ed76da5c15fa72b687f1cebd5931/ (Accessed December 12, 2025).
- Eurasian Economic Union (2019a). О классификаторе лекарственноГО растительноГО сырья [Passport of the medicinal plant raw materials classifier]. Available online at: <https://www.alta.ru/tamdoc/19kr0059/> (Accessed December 12, 2025).
- Eurasian Economic Union (2019b). О Руководстве По выбору тестов и критериев Приемлемости для составления спецификаций на лекарственное растительное сырье, растительные фармацевтические субстанции (Препараты на основе лекарственноГО растительноГО сырья) и лекарственные растительные Препараты [Guidelines for the selection of tests and acceptance criteria for the preparation of specifications for medicinal plant materials, herbal pharmaceutical substances (herbal preparations) and herbal medicinal products]. Available online at: <https://www.alta.ru/tamdoc/19kr0006/> (Accessed December 12, 2025).
- Eurasian Economic Union (2019c). О руководстве По контролю рисков микробной контаминации лекарственноГО растительноГО сырья, растительных фармацевтических субстанций (Препаратов на основе лекарственноГО растительноГО сырья) и лекарственных растительных Препаратов [Guidelines for Controlling the Risks of Microbial Contamination of Medicinal Plant Materials, herbal pharmaceutical substances (drugs based on medicinal plant materials) and herbal medicinal products]. Available online at: <https://docs.eaeunion.org/en/documents/337/4592/> (Accessed December 12, 2025).
- Eurasian Economic Union (2020). О фармакопее ?вразийскоГО экономического союза [the pharmacopoeia of the EAEU]. Available online at: <https://docs.eaeunion.org/en/documents/247/5266/> (Accessed December 12, 2025).
- Eurasian Economic Union (2021a). О Руководстве По оценке качества лекарственных Препаратов на основе комбинаций лекарственноГО растительноГО сырья, растительных фармацевтических субстанций (Препаратов на основе лекарственноГО растительноГО сырья) [Guidelines for assessing the quality of medicinal products based on combinations of medicinal plant material and (or) herbal pharmaceutical substances (drugs based on medicinal herbal raw materials)]. Available online at: https://regulation.eaeunion.org/upload/iblock/98a/hhn70f9145g8h2tiaycwad82pr736h31/pd_13072020_mdodc.pdf (Accessed December 12, 2025).
- Eurasian Economic Union (2021b). Требования к исследованию стабильности растительных фармацевтических субстанций (Препаратов на основе лекарственноГО растительноГО сырья) и лекарственных растительных Препаратов [Requirements for the analysis of herbal pharmaceutical substances (preparations based on medicinal plant raw materials) and herbal medicinal products stability]. Available online at: <https://www.alta.ru/tamdoc/21kr0169/> (Accessed December 12, 2025).
- Eurasian Economic Union (2022). О Руководстве По указанию наименования и содержания лекарственноГО растительноГО сырья, растительных фармацевтических субстанций (Препаратов на основе лекарственноГО растительноГО сырья) в общей характеристике лекарственноГО Препарата для медицинскоГО Применения, инструкции По медицинскому Применению (листке-вкладыше) и маркировке лекарственноГО растительноГО Препарата [Guidelines for indicating the name and content of medicinal plant materials, herbal pharmaceutical substances (drugs based on medicinal plant materials) in the general characteristics of a medicinal product for medical use, instructions for medical use (leaflet) and labeling of the medicinal product]. Available online at: <https://www.alta.ru/tamdoc/22rk0020/> (Accessed December 12, 2025).
- European Medicines Agency (2004). European Union monographs and list entries. Available online at: <https://www.ema.europa.eu/en/human-regulatory-overview/herbal-medicinal-products/european-union-monographs-list-entries> (Accessed April 13, 2025).
- European Medicines Agency (2005). Template for submission of a request for scientific support and advice on a traditional herbal medicinal product. Available online at: <https://www.ema.europa.eu/en/template-submission-request-scientific-support-advice-traditional-herbal-medicinal-product> (Accessed October 12, 2025).
- European Medicines Agency (2006a). Clinical assessment of fixed combinations of herbal substances/herbal preparations. Available online at: <https://www.ema.europa.eu/en/clinical-assessment-fixed-combinations-herbal-substances-herbal-preparations-scientific-guideline> (Accessed October 12, 2025).
- European Medicines Agency (2006b). Guideline on the clinical assessment of fixed combinations of herbal substances/ herbal preparations. Available online at: [https://www.ema.europa.eu/en/clinical-assessment-\(xed-combinations-herbal-substancesherbal-preparations-scientific-guideline#current-effective-version-9351](https://www.ema.europa.eu/en/clinical-assessment-(xed-combinations-herbal-substancesherbal-preparations-scientific-guideline#current-effective-version-9351) (Accessed October 12, 2025).
- European Medicines Agency (2011). Guidance for applicants seeking scientific support and advice on traditional herbal medicinal products. Available online at: <https://www.ema.europa.eu/en/guidance-companies-seeking-scientific-support-advice-traditional-herbal-medicinal-products> (Accessed October 12, 2025).
- European Medicines Agency (2008a). Assessment of genotoxicity of herbal substances/preparations. Available online at: <https://www.ema.europa.eu/en/assessment-genotoxicity-herbal-substances-preparations-scientific-guideline> (Accessed October 12, 2025).
- European Medicines Agency (2008b). Quality of combination herbal medicinal products/traditional herbal medicinal products. Available online at: <https://www.ema.europa.eu/en/quality-combination-herbal-medicinal-products-traditional-herbal-medicinal-products-scientific-guideline> (Accessed October 12, 2025).
- European Medicines Agency (2010a). Guideline on declaration of herbal substances and herbal preparations in herbal medicinal products/traditional herbal medicinal products. Available online at: <https://www.ema.europa.eu/en/declaration-herbal-substances-herbal-preparations-herbal-medicinal-products-traditional-herbal-medicinal-products-scientific-guideline> (Accessed October 12, 2025).
- European Medicines Agency (2010b). Reflection paper on the level of purification of extracts to be considered as herbal preparations. Available online at: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-level-purification-extracts-be-considered-herbal-preparations_en.pdf (Accessed October 12, 2025).
- European Medicines Agency (2010c). Selection of test materials for genotoxicity testing for traditional herbal medicinal products/herbal medicinal products. Available online at: <https://www.ema.europa.eu/en/selection-test-materials-genotoxicity-testing-traditional-herbal-medicinal-products-herbal-medicinal-products-scientific-guideline> (Accessed October 12, 2025).
- European Medicines Agency (2016a). Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products. Available online at: <https://www.ema.europa.eu/en/guideline-use-ctd-format-preparation-registration-application-traditional-herbal-medicinal-products> (Accessed October 12, 2025).
- European Medicines Agency (2016b). Public statement on contamination of herbal medicinal products/traditional herbal medicinal products with pyrrolizidine alkaloids. Available online at: https://www.ema.europa.eu/en/documents/public-statement/public-statement-contamination-herbal-medicinal-products-traditional-herbal-medicinal-products-pyrrolizidine-alkaloids_en.pdf (Accessed October 12, 2025).
- European Medicines Agency (2017). Assessment of clinical safety and efficacy in the preparation of EU herbal monographs for well-established and traditional herbal medicinal products. Available online at: <https://www.ema.europa.eu/en/assessment-clinical-safety-efficacy-preparation-eu-herbal-monographs-well-established-traditional-herbal-medicinal-products-scientific-guideline> (Accessed October 12, 2025).
- European Medicines Agency (2019). Non-clinical documentation in applications for marketing authorisation/ registration of well-established and traditional herbal medicinal products. Available online at: <https://www.ema.europa.eu/en/non-clinical-documentation-applications-marketing-authorisation-registration-well-established-traditional-herbal-medicinal-products-scientific-guideline> (Accessed October 12, 2025).
- European Medicines Agency (2022a). Guideline on quality of herbal medicinal products/traditional herbal medicinal products. Available online at: https://www.ema.europa.eu/en/documents/scientific-guideline/final-guideline-quality-herbal-medicinal-product-traditional-herbal-medicinal-products-revision-3_en.pdf (Accessed October 12, 2025).
- European Medicines Agency (2022b). Quality of herbal medicinal products/ traditional herbal medicinal products. Available online at: <https://www.ema.europa.eu/en/quality-herbal-medicinal-products-traditional-herbal-medicinal-products-scientific-guideline> (Accessed October 12, 2025).
- European Medicines Agency (2022c). Specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and herbal medicinal products/ traditional herbal medicinal products - scientific guideline. Available online at: <https://www.ema.europa.eu/en/specifications-test-procedures-acceptance-criteria-herbal-substances-herbal-preparations-herbal-medicinal-products-traditional-herbal-medicinal-products-scientific-guideline> (Accessed October 12, 2025).
- European Pharmacopoeia (2022). European pharmacopoeia (Ph. Eur.) 11th Edition. Available online at: <https://www.edqm.eu/en/european-pharmacopoeia-ph-eur-11th-edition#7B%22468369%22%5B0%5D%7D> (Accessed October 20, 2025).
- Frolova, L. N., Kovaleva, E. L., Shelestova, V. V., Kuteynikov, V. Y., and Olenina, N. G. (2024). Challenges associated with forming generic names for herbal medicinal products. РеГультаторные исследования и эксПертиза лекарственных средств 14 (2), 138–158. doi:10.30895/1991-2919-2024-14-2-138-158
- Gagnier, J. J., Boon, H., Rochon, P., Moher, D., Barnes, J., Bombardier, C., et al. (2006). Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. *Ann. Intern. Med.* 144 (5), 364–367. doi:10.7326/0003-4819-144-5-200603070-00013
- Glasgow, R. E., Vogt, T. M., and Boles, S. M. (1999). Evaluating the public health impact of health promotion interventions: the RE-AIM framework. *Am. J. Public Health* 89 (9), 1322–1327. doi:10.2105/ajph.89.9.1322
- Greenlee, H., Balneaves, L. G., Carlson, L. E., Cohen, M., Deng, G., Hershman, D., et al. (2014). Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. *J. Natl. Cancer Inst. Monogr.* 2014 (50), 346–358. doi:10.1093/jncimonographs/igu041

- Greenlee, H., DuPont-Reyes, M. J., Balneaves, L. G., Carlson, L. E., Cohen, M. R., Deng, G., et al. (2017). Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. *CA Cancer J. Clin.*, 67 (3): 194–232. doi:10.3322/caac.21397
- Guidelines International Network (NA). Guideline implementation planning checklist. Available online at: <https://g-i-n.net/wp-content/uploads/2021/04/Guideline-Implementation-Planning-Checklist.pdf> (Accessed April 13, 2025).
- Guise, J. M., Butler, M. E., Chang, C., Viswanathan, M., Pigott, T., Tugwell, P., et al. (2017). AHRQ series on complex intervention systematic reviews-paper 6: PRISMA-CI extension statement and checklist. *J. Clin. Epidemiol.* 90, 43–50. doi:10.1016/j.jclinepi.2017.06.016
- Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., et al. (2011). GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J. Clin. Epidemiol.* 64 (4), 383–394. doi:10.1016/j.jclinepi.2010.04.026
- Guyatt, G. H., Oxman, A. D., Kunz, R., Atkins, D., Brozek, J., Vist, G., et al. (2011). GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J. Clin. Epidemiol.* 64 (4), 395–400. doi:10.1016/j.jclinepi.2010.09.012
- Healthcare Information and Management Systems Society (2024). Assessing digital maturity: the DigiMTM digital maturity model for health systems. Available online at: https://www.damoconsulting.net/wp-content/uploads/2024/09/DigiM_whitepaper_updated_sept2024.pdf (Accessed October 13, 2025).
- Heidari, S., Babor, T. F., De Castro, P., Tort, S., and Curno, M. (2016). Sex and gender equity in research: rationale for the SAGER guidelines and recommended use. *Res. Integr. Peer Rev.* 1, 2. doi:10.1186/s41073-016-0007-6
- Heinrich, M., Lardos, A., Leonti, M., Weckerle, C., Willcox, M., Applequist, W., et al. (2018). Best practice in research: consensus statement on ethnopharmacological field studies - ConSEFS. *J. Ethnopharmacol.* 211, 329–339. doi:10.1016/j.jep.2017.08.015
- Heinrich, M., Jalil, B., Abdel-Tawab, M., Echeverria, J., Kulić, Ž., McGaw, L. J., et al. (2022). Best practice in the chemical characterisation of extracts used in pharmacological and toxicological research-The ConPhyMP-Guidelines. *Front. Pharmacol.* 13, 953205. doi:10.3389/fphar.2022.953205
- Hopewell, S., Chan, A. W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., et al. (2025). CONSORT 2025 statement: updated guideline for reporting randomised trials. *Lancet* 405 (10489), 1633–1640. doi:10.1016/s0140-6736(25)00672-5
- Hróbjartsson, A., Boutron, I., Hopewell, S., Moher, D., Schulz, K. F., Collins, G. S., et al. (2025). SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials. *BMJ* 389, e081660. doi:10.1136/bmj-2024-081660
- Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A. H., Carswell, C., et al. (2022). Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. *Value Health* 25 (1), 3–9. doi:10.1016/j.jval.2021.11.1351
- Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., et al. (2015). The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann. Intern. Med.* 162 (11), 777–784. doi:10.7326/m14-2385
- International Committee of Medical Journal Editors (2025). Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. Available online at: <https://www.icmje.org/icmje-recommendations.pdf> (Accessed August 25, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2000a). E10 choice of control group and related issues in clinical trials. Available online at: https://database.ich.org/sites/default/files/E10_Guideline.pdf (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2000b). Q7 good manufacturing practice guide for active pharmaceutical ingredients. Available online at: <https://database.ich.org/sites/default/files/Q7%20Guideline.pdf> (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2000c). S7A safety pharmacology studies for human Pharmaceuticals. Available online at: https://database.ich.org/sites/default/files/S7A_Guideline.pdf (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2002). Q1D Bracketing and Matrixing designs for stability testing of new drug substances and products. Available online at: <https://database.ich.org/sites/default/files/Q1D%20Guideline.pdf> (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2003a). E2D post-approval safety data management: definitions and standards for expedited reporting. Available online at: https://database.ich.org/sites/default/files/E2D_Guideline.pdf (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2003b). Q1A(R2) stability testing of new drug substances and products. Available online at: <https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf> (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2003c). Q1E evaluation of stability data. Available online at: <https://database.ich.org/sites/default/files/Q1E%20Guideline.pdf> (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2004a). E2E pharmacovigilance planning. Available online at: https://database.ich.org/sites/default/files/E2E_Guideline.pdf (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2004b). Q5E comparability of biotechnological/biological products subject to changes in their manufacturing process. Available online at: <https://database.ich.org/sites/default/files/Q5E%20Guideline.pdf> (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2005a). Q2(R2) validation of analytical procedures: text and methodology. Available online at: https://database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guideline_2023_1130.pdf (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2005b). S7B the non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human Pharmaceuticals. Available online at: https://database.ich.org/sites/default/files/S7B_Guideline.pdf (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2005c). S8 immunotoxicity studies for human pharmaceuticals. Available online at: https://database.ich.org/sites/default/files/S8_Guideline_0.pdf (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2006a). Q3A(R2) Impurities in new drug substances. Available online at: <https://database.ich.org/sites/default/files/Q3A%28R2%29%20Guideline.pdf> (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2006b). Q3B(R2) Impurities in new drug products. Available online at: <https://database.ich.org/sites/default/files/Q3B%28R2%29%20Guideline.pdf> (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2007a). E15 definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. Available online at: https://database.ich.org/sites/default/files/E15_Guideline.pdf (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2007b). Q4B evaluation and recommendation of pharmacopoeial texts for Use in the ICH regions. Available online at: <https://database.ich.org/sites/default/files/Q4B%20Guideline.pdf> (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2008a). Q10 pharmaceutical quality system. Available online at: <https://database.ich.org/sites/default/files/Q10%20Guideline.pdf> (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2008b). S1C(R2) Dose selection for Carcinogenicity studies of Pharmaceuticals. Available online at: <https://database.ich.org/sites/default/files/S1C%28R2%29%20Guideline.pdf> (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2009a). M3(R2) guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Available online at: https://database.ich.org/sites/default/files/M3_R2_Guideline.pdf (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2009b). Q8(R2) pharmaceutical development. Available online at: <https://database.ich.org/sites/default/files/Q8%28R2%29%20Guideline.pdf> (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2009c). S9 nonclinical evaluation for anticancer pharmaceuticals. Available online at: https://database.ich.org/sites/default/files/S9_Guideline.pdf (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2010a). E2F development safety update report. Available online at: https://database.ich.org/sites/default/files/E2F_Guideline.pdf (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2010b). E16 biomarkers related to drug or biotechnology product development: context, structure and format of qualification submissions. Available online at: https://database.ich.org/sites/default/files/E16_Guideline.pdf (Accessed October 13, 2025).
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2010c). Q4B Annex 1(R1) residue on ignition/sulphated ash general chapter. Available online at: <https://database.ich.org/sites/default/files/Q4B%20Annex%201%28R1%29%20Guideline.pdf> (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2010d). Q4B Annex 2(R1) test for extractable volume of parenteral preparations general chapter. Available online at: <https://database.ich.org/sites/default/files/Q4B%20Annex%202%28R1%29%20Guideline.pdf> (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2010e). Q4B Annex 3(R1) test for particulate contamination: sub-visible particles general chapter. Available online at: <https://database.ich.org/sites/default/files/Q4B%20Annex%203%28R1%29%20Guideline.pdf> (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2010f). Q4B annex 4A(R1) microbiological examination of non-sterile products: microbial enumeration tests general chapter. Available online at: <https://database.ich.org/sites/default/files/Q4B%20Annex4A%28R1%29%20Guideline.pdf> (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2010g). Q4B Annex 4B(R1) microbiological examination of non-sterile products: tests for specified micro-organisms general chapter. Available online at: <https://database.ich.org/sites/default/files/Q4B%20Annex4B%28R1%29%20Guideline.pdf> (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2010h). Q4B annex 4C(R1) microbiological examination of non-sterile products: acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use general chapter. Available online at: <https://database.ich.org/sites/default/files/Q4B%20Annex4C%28R1%29%20Guideline.pdf> (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2010i). Q4B Annex 5(R1) disintegration test general chapter. Available online at: <https://database.ich.org/sites/default/files/Q4B%20Annex%205%28R1%29%20Guideline.pdf> (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2010j). Q4B annex 8(R1) sterility test general chapter. Available online at: <https://database.ich.org/sites/default/files/Q4B%20Annex%208%28R1%29%20Guideline.pdf> (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2010k). Q4B Annex 9(R1) tablet friability general chapter. Available online at: <https://database.ich.org/sites/default/files/Q4B%20Annex%209%28R1%29%20Guideline.pdf> (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2010l). Q4B annex 10(R1) polyacrylamide gel electrophoresis general chapter. Available online at: <https://database.ich.org/sites/default/files/Q4B%20Annex%2010%28R1%29%20Guideline.pdf> (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2010m). Q4B annex 11 capillary electrophoresis general chapter. Available online at: <https://database.ich.org/sites/default/files/Q4B%20Annex%2011%20Guideline.pdf> (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2010n). Q4B annex 12 analytical sieving general chapter. Available online at: <https://database.ich.org/sites/default/files/Q4B%20Annex%2012%20Guideline.pdf> (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2012a). E2B(R3) clinical safety data management: data elements for transmission of individual case safety reports (ICSRs). Available online at: https://database.ich.org/sites/default/files/ICH_E2BR3_EWG_WorkPlan_2025_0221.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2012b). E2C(R2) periodic benefit-risk evaluation report. Available online at: https://database.ich.org/sites/default/files/E2C_R2_Guideline.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2012c). Q4B annex 14 bacterial endotoxins test general chapter. Available online at: <https://database.ich.org/sites/default/files/Q4B%20Annex%2014%20Guideline.pdf> (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2012d). Q11 development and manufacture of drug substances (chemical entities and biotechnological/biological entities). Available online at: <https://database.ich.org/sites/default/files/Q11%20Guideline.pdf> (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2013). S10 Photosafety evaluation of pharmaceuticals. Available online at: https://database.ich.org/sites/default/files/S10_Guideline.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2016). E6(R2) good clinical practice (GCP). Available online at: https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2017a). E11(R1) clinical investigation of medicinal products in the pediatric population: guideline and addendum. Available online at: https://database.ich.org/sites/default/files/E11_R1_Addendum.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2017b). E17 general principles for planning and design of multi-regional clinical trials. Available online at: https://database.ich.org/sites/default/files/E17EWG_Step4_2017_1116.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2017c). E18 genomic sampling and management of genomic data. Available online at: https://database.ich.org/sites/default/files/E18_Guideline.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2019a). E9(R1) addendum: statistical principles for clinical trials. Available online at: https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2019b). M9 biopharmaceutics classification system-based biowaivers. Available online at: https://database.ich.org/sites/default/files/M9_Guideline_Step4_2019_1116.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2019c). Q12 technical and regulatory considerations for pharmaceutical product lifecycle management m9 biopharmaceutics classification system-based biowaivers. Available online at: https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2020). S5(R3) revision of S5 guideline on detection of toxicity to reproduction for human pharmaceuticals. Available online at: https://database.ich.org/sites/default/files/S5-R3_Step4_Guideline_2020_0218_1.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2021). E8(R1) general considerations for clinical studies. Available online at: https://database.ich.org/sites/default/files/ICH_E8-R1_Guideline_Step4_2021_1006.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2022a). E19 A selective approach to safety data collection in specific late-stage pre-approval or post-approval clinical trials. Available online at: https://database.ich.org/sites/default/files/ICH_E19_Guideline_Step4_2022_0826_0.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2022b). M10 bioanalytical method validation and study sample analysis. Available online at: https://database.ich.org/sites/default/files/M10_Guideline_Step4_2022_0524.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2022c). Q3D(R2) guideline for elemental impurities. Available online at: https://database.ich.org/sites/default/files/Q3D-R2_Guideline_Step4_2022_0308.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2022d). Q13 continuous manufacturing of drug substances and drug products. Available online at: https://database.ich.org/sites/default/files/ICH_Q13_Step4_Guideline_2022_1116.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2022e). S1B(R1) testing for carcinogenicity of Pharmaceuticals. Available online at: https://database.ich.org/sites/default/files/S1B-R1_FinalGuideline_2022_0719.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2023a). M7(R2) assessment and control of DNA reactive (Mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. Available online at: https://database.ich.org/sites/default/files/ICH_M7%28R2%29_Guideline_Step4_2023_0216_0.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2023b). Q9(R1) quality risk management. Available online at: https://database.ich.org/sites/default/files/ICH_Q9%28R1%29_Guideline_Step4_2025_0115.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2023c). Q14 analytical procedure development. Available online at: https://database.ich.org/sites/default/files/ICH_Q14_Guideline_2023_1116_1.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2024a). M12 drug interaction studies. Available online at: https://database.ich.org/sites/default/files/ICH_M12_Step4_Guideline_2024_0521_0.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2024b). M13A EWG bioequivalence for immediate-release solid oral dosage forms. Available online at: https://database.ich.org/sites/default/files/M13A_EWG_Bioequivalence_2024_0521_0.pdf (Accessed October 13, 2025).

org/sites/default/files/ICH_M13A_Step4_Final_Guideline_2024_0723.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2024c). Q3C(R9) guideline for residual solvents. Available online at: https://database.ich.org/sites/default/files/ICH_Q3C%28R9%29_Guideline_MinorRevision_2024_2024_Approved.pdf (Accessed October 13, 2025).

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2024d). Q4B(R1) evaluation and recommendation of pharmacopoeial texts for Use in the ICH regions. Available online at: https://database.ich.org/sites/default/files/ICH_Q4B%28R1%29_Guideline_2024_0605.pdf (Accessed October 13, 2025).

International Federation of Orthopaedic Manipulative Physical Therapists (2012). IFOMPT IM guidance second submission. Available online at: <https://www.ifompt.org/site/ifompt/files/pdf/StandardsCommittee/StandardsCommitteeDocuments/IFOMPTIMguidancesecondsubmission.pdf> (Accessed October 13, 2025).

International Federation of Orthopaedic Manipulative Physical Therapists (2016a). IFOMPT standards document definitive 2016. Available online at: <https://www.ifompt.org/site/ifompt/IFOMPTStandardsDocumentdefinitive2016.pdf> (Accessed October 13, 2025).

International Federation of Orthopaedic Manipulative Physical Therapists (2016b). IFOMPT template programme mapping to standards document. Available online at: <https://www.ifompt.org/site/ifompt/files/pdf/Standards%20Committee/Standards%20Committee%20Documents/IFOMPT%20Template%20Programme%20Mapping%20to%20Standards%20Document.pdf> (Accessed October 13, 2025).

International Federation of Orthopaedic Manipulative Physical Therapists (2017). IFOMPT recommendations regarding the research project component of OMT programmes. Available online at: https://www.ifompt.org/site/ifompt/files/pdf/StandardsCommittee/StandardsCommitteeDocuments/IFOMPT_research_project_guidance_MOs.pdf (Accessed October 13, 2025).

International Organization for Standardization (NA). Implementation of the WHO traditional medicine strategy 2014–2023. Geneva, Switzerland. Available online at: <https://www.who.int/activities/implementation-of-the-who-traditional-medicine-strategy-2014-2023> (Accessed April 13, 2025).

International Organization for Standardization (2014a). ISO 17217-1:2014 — traditional Chinese medicine — ginseng seeds and seedlings — Part 1: *Panax ginseng* C.A. Meyer. Available online at: <https://www.iso.org/standard/63485.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2014b). ISO 17218:2014 — sterile acupuncture needles for single use. Available online at: <https://www.iso.org/standard/59443.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2014c). ISO/TS 17938:2014 — health informatics — Semantic network framework of traditional Chinese medicine language system. Available online at: <https://www.iso.org/standard/61071.html> (Accessed October 12, 2025).

International Organization for Standardization (2014d). ISO/TS 17948:2014 — health informatics — traditional Chinese medicine literature metadata. Available online at: <https://www.iso.org/standard/61081.html> (Accessed October 12, 2025).

International Organization for Standardization (2015a). ISO 18664:2015 — traditional Chinese Medicine — Determination of heavy metals in herbal medicines used in Traditional Chinese Medicine. Available online at: <https://www.iso.org/standard/63150.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2015b). ISO/TS 16277-1:2015 — health informatics — Categorial structures of clinical findings in traditional medicine — Part 1: traditional Chinese, Japanese and Korean medicine. Available online at: <https://www.iso.org/standard/56044.html> (Accessed October 12, 2025).

International Organization for Standardization (2015c). ISO/TS 16843-2:2015 Health informatics — Categorial structures for representation of acupuncture — Part 2: Needling. Available online at: <https://www.iso.org/standard/69409.html> (Accessed October 12, 2025).

International Organization for Standardization (2015d). ISO/TS 18790-1:2015 — health informatics — Profiling framework and classification for Traditional Medicine informatics standards development — Part 1: traditional Chinese Medicine. Available online at: <https://www.iso.org/standard/63381.html> (Accessed October 12, 2025).

International Organization for Standardization (2016a). ISO 18362:2016 — Manufacture of cell-based health care products — control of microbial risks during processing. Available online at: <https://www.iso.org/standard/62244.html> (Accessed October 12, 2025).

International Organization for Standardization (2016b). ISO 18668-1:2016 — traditional Chinese medicine — Coding system for Chinese medicines — Part 1: Coding rules for Chinese medicines. Available online at: <https://www.iso.org/standard/63155.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2016c). ISO 18746:2016 — traditional Chinese medicine — sterile intradermal acupuncture needles for single use. Available online at: <https://www.iso.org/standard/63263.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2016d). ISO/TS 16843-1:2016 Health informatics — Categorial structures for representation of acupuncture — Part 1: acupuncture points. Available online at: <https://www.iso.org/standard/69406.html> (Accessed October 12, 2025).

International Organization for Standardization (2017a). ISO 18662-1:2017 — traditional Chinese medicine — vocabulary — Part 1: Chinese materia medica. Available online at: <https://www.iso.org/standard/63148.html?browse=tc> (Accessed October 13, 2025).

International Organization for Standardization (2017b). ISO 18668-2:2017 — traditional Chinese medicine — coding system for Chinese medicines — Part 2: codes for decoction pieces. Available online at: <https://www.iso.org/standard/64958.html?browse=tc> (Accessed October 13, 2025).

International Organization for Standardization (2017c). ISO 18668-3:2017 — traditional Chinese medicine — Coding system for Chinese medicines — Part 3: codes for Chinese materia medica. Available online at: <https://www.iso.org/standard/68354.html?browse=tc> (Accessed October 13, 2025).

International Organization for Standardization (2017d). ISO 18668-4:2017 — traditional Chinese medicine — coding system for Chinese medicines — Part 4: codes for granule forms of individual medicinals for prescriptions. Available online at: <https://www.iso.org/standard/68355.html?browse=tc> (Accessed October 13, 2025).

International Organization for Standardization (2017e). ISO 19465:2017 — traditional Chinese medicine — categories of traditional Chinese medicine (TCM) clinical terminological systems. Available online at: <https://www.iso.org/standard/64962.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2017f). ISO 19610:2017 — traditional Chinese medicine — general requirements for industrial manufacturing process of red ginseng. *Panax ginseng* C.A. Meyer. Available online at: <https://www.iso.org/standard/65462.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2017g). ISO 19611:2017 — traditional Chinese medicine — air extraction cupping device. Available online at: <https://www.iso.org/standard/65463.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2017h). ISO 19614:2017 — traditional Chinese medicine — pulse graph force transducer. Available online at: <https://www.iso.org/standard/65479.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2017i). ISO 19824:2017 — traditional Chinese medicine — *Schisandra chinensis* (Turcz.) Baill. seeds and seedlings. Available online at: <https://www.iso.org/standard/66278.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2017j). ISO 20308:2017 — traditional Chinese medicine — gua Sha instruments. Available online at: <https://www.iso.org/standard/67623.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2017k). ISO 20311:2017 — traditional Chinese medicine — *Salvia miltiorrhiza* seeds and seedlings. Available online at: <https://www.iso.org/standard/67644.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2017l). ISO 20333:2017 — traditional Chinese medicine — Coding rules for Chinese medicines in supply chain management. Available online at: <https://www.iso.org/standard/67712.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2017m). ISO 20408:2017 — traditional Chinese medicine — *Panax notoginseng* seeds and seedlings. Available online at: <https://www.iso.org/standard/67920.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2017n). ISO 20409:2017 — traditional Chinese medicine — *Panax notoginseng* root and rhizome. Available online at: <https://www.iso.org/standard/67921.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2017o). ISO 20498-2:2017 — traditional Chinese medicine — Computerized tongue image analysis system — Part 2: light environment. Available online at: <https://www.iso.org/standard/68215.html?browse=tc> (Accessed October 13, 2025).

International Organization for Standardization (2017p). ISO/TS 16843-3:2017 Health informatics — Categorial structures for representation of acupuncture Part 3: moxibustion. Available online at: <https://www.iso.org/standard/67899.html> (Accessed October 12, 2025).

International Organization for Standardization (2017q). ISO/TS 16843-4:2017 Health informatics — Categorial structures for representation of acupuncture Part 4: Meridian and collateral channels. Available online at: <https://www.iso.org/standard/68587.html> (Accessed October 12, 2025).

International Organization for Standardization (2018a). ISO 19617:2018 — traditional Chinese medicine — general requirements for the manufacturing process of natural products. Available online at: <https://www.iso.org/standard/65504.html?browse=tc> (Accessed October 12, 2025).

- International Organization for Standardization (2018b). ISO 20334:2018 — traditional Chinese medicine — Coding system of formulae. Available online at: <https://www.iso.org/standard/67713.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2018c). ISO 20493:2018 — traditional Chinese medicine — Infrared moxibustion-like instrument. Available online at: <https://www.iso.org/standard/68210.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2018d). ISO 20495:2018 — traditional Chinese medicine — Skin electrical resistance measurement devices. Available online at: <https://www.iso.org/standard/68212.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2018e). ISO 21315:2018 — traditional Chinese medicine — Ganoderma lucidum fruiting body. Available online at: <https://www.iso.org/standard/70519.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2018f). ISO 21371:2018 — traditional Chinese medicine — labelling requirements of products intended for oral or topical use. Available online at: <https://www.iso.org/standard/70793.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2018g). ISO/TR 20520:2018 — traditional Chinese medicine — infection control for acupuncture treatment. Available online at: <https://www.iso.org/standard/75169.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2018h). ISO/TR 23021:2018 — traditional Chinese medicine — controlled vocabulary on Japanese Kampo crude drugs. Available online at: <https://www.iso.org/standard/74339.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2018i). ISO/TR 23022:2018 — traditional Chinese medicine — controlled vocabulary on Japanese Kampo formulas and the indication codes for the products. Available online at: <https://www.iso.org/standard/74340.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2019a). ISO 20487:2019 — traditional Chinese medicine — test method of single-use acupuncture needles for electrical stimulation. Available online at: <https://www.iso.org/standard/68192.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2019b). ISO 20498-1:2019 — traditional Chinese medicine — Computerized tongue image analysis system — Part 1: general requirements. Available online at: <https://www.iso.org/standard/68216.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2019c). ISO 20740:2019 Martial arts — Wushu Taiji Sword — requirements and test method. Available online at: <https://www.iso.org/standard/68952.html> (Accessed October 12, 2025).
- International Organization for Standardization (2019d). ISO 21291:2019 — traditional Chinese medicine —therapeutic fumigation devices. Available online at: <https://www.iso.org/standard/70469.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2019e). ISO 21300:2019 — traditional Chinese medicine — guidelines and specification for Chinese materia medica. Available online at: <https://www.iso.org/standard/70496.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2019f). ISO 21314:2019 — traditional Chinese medicine — *Salvia miltiorrhiza* root and rhizome. Available online at: <https://www.iso.org/standard/70518.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2019g). ISO 21316:2019 — traditional Chinese medicine — *Isatis indigotica* root. Available online at: <https://www.iso.org/standard/70520.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2019h). ISO 21317:2019 — traditional Chinese medicine — *Lonicera japonica* flower. Available online at: <https://www.iso.org/standard/70521.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2019i). ISO 21366:2019 — traditional Chinese medicine — general requirements for smokeless moxibustion devices. Available online at: <https://www.iso.org/standard/70791.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2019j). ISO 21370:2019 — traditional Chinese medicine — *Dendrobium officinale* stem. Available online at: <https://www.iso.org/standard/70792.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2019k). ISO 22212:2019 — traditional Chinese medicine — *Gastrodia elata* tuber. Available online at: <https://www.iso.org/standard/72883.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2019l). ISO 22584:2019 — traditional Chinese medicine — *Angelica sinensis* root. Available online at: <https://www.iso.org/standard/73507.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2019m). ISO/TR 20498-5:2019 — traditional Chinese medicine — Computerized tongue image analysis system — Part 5: method of acquisition and expression of tongue colour and tongue coating colour. Available online at: <https://www.iso.org/standard/70523.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2019n). ISO/TS 16843-5:2019 health informatics — Categorical structures for representation of acupuncture — Part 5: cupping. Available online at: <https://www.iso.org/standard/71053.html> (Accessed October 12, 2025).
- International Organization for Standardization (2019o). ISO/TS 20758:2019 — traditional Chinese medicine — Abdominal physiological parameter detectors. Available online at: <https://www.iso.org/standard/68984.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2019p). ISO/TS 22558:2019 — health informatics — classification of traditional Chinese medicine data sets. Available online at: <https://www.iso.org/standard/73437.html> (Accessed October 12, 2025).
- International Organization for Standardization (2019q). ISO/TS 22773:2019 — health Informatics — Categorical structures for the representation of the decocting process in traditional Chinese medicine. Available online at: <https://www.iso.org/standard/73899.html> (Accessed October 12, 2025).
- International Organization for Standardization (2019r). ISO/TS 22990:2019 — traditional Chinese medicine — Categories of clinical terminological system to support the integration of clinical terms from traditional Chinese medicine and Western medicine. Available online at: <https://www.iso.org/standard/74298.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2020a). ISO 17511:2020 *in vitro* diagnostic medical devices — requirements for establishing metrological traceability of values assigned to calibrators, trueness control materials and human samples. Available online at: <https://www.iso.org/standard/69984.html> (Accessed October 12, 2025).
- International Organization for Standardization (2020b). ISO 18615:2020 — traditional Chinese medicine — general requirements of electric radial pulse tonometric devices. Available online at: <https://www.iso.org/standard/71491.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2020c). ISO 18662-2:2020 — traditional Chinese medicine — vocabulary — Part 2: processing of Chinese materia medica. Available online at: <https://www.iso.org/standard/71024.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2020d). ISO 21151:2020 *in vitro* diagnostic medical devices — requirements for international harmonisation protocols establishing metrological traceability of values assigned to calibrators and human samples. Available online at: <https://www.iso.org/standard/69985.html> (Accessed October 12, 2025).
- International Organization for Standardization (2020e). ISO 21292:2020 — traditional Chinese medicine — electric heating moxibustion equipment. Available online at: <https://www.iso.org/standard/70470.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2020f). ISO 22213:2020 — traditional Chinese medicine — Glass cupping device. Available online at: <https://www.iso.org/standard/72884.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2020g). ISO 22217:2020 — traditional Chinese medicine —storage requirements for raw materials and decoction pieces. Available online at: <https://www.iso.org/standard/72894.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2020h). ISO 22236:2020 — traditional Chinese medicine —Thread-embedding acupuncture needle for single use. Available online at: <https://www.iso.org/standard/72919.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2020i). ISO 22256:2020 — traditional Chinese medicine — Detection of irradiated natural products by photostimulated luminescence. Available online at: <https://www.iso.org/standard/72985.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2020j). ISO 22258:2020 — traditional Chinese medicine — determination of pesticide residues in natural products by gas chromatography. Available online at: <https://www.iso.org/standard/72987.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2020k). ISO 22283:2020 — traditional Chinese medicine — determination of aflatoxins in natural products by LC-FLD. Available online at: <https://www.iso.org/standard/73030.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2020l). ISO 22590:2020 — traditional Chinese medicine — Determination of sulfur dioxide in natural products by titration. Available online at: <https://www.iso.org/standard/73513.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2020m). ISO 22894:2020 — traditional Chinese medicine — pulse waveform format. Available online at: <https://www.iso.org/standard/74088.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2020n). ISO 22988:2020 — traditional Chinese medicine — *Astragalus mongholicus* root. Available online at: <https://www.iso.org/standard/74288.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2020o). ISO 23191:2020 — traditional Chinese medicine — determination of selected Aconitum

alkaloids by high-performance liquid chromatography (HPLC). Available online at: <https://www.iso.org/standard/74849.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2020p). ISO 23193:2020 — traditional Chinese medicine — *Lycium barbarum* and *Lycium chinense* fruit. Available online at: <https://www.iso.org/standard/74851.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2020q). ISO/TS 20498-4:2020 — traditional Chinese medicine — Computerized tongue image analysis system — Part 4: peripheral visual instruments. Available online at: <https://www.iso.org/standard/70795.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2020r). ISO/TS 21310:2020 — traditional Chinese medicine — Microscopic examination of medicinal herbs. Available online at: <https://www.iso.org/standard/70514.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2020s). ISO/TS 21831:2020 — information model of Chinese materia medica processing. Available online at: <https://www.iso.org/standard/72079.html> (Accessed October 12, 2025).

International Organization for Standardization (2020t). ISO/TS 23030:2020 — traditional Chinese medicine — clinical document specification for prescription of traditional Chinese medicine decoction pieces. Available online at: <https://www.iso.org/standard/74354.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2020u). Traditional Chinese medicine — Computerized tongue image analysis system Part 3: colour chart. Available online at: <https://www.iso.org/standard/70794.html> (Accessed October 13, 2025).

International Organization for Standardization (2021a). ISO 18666:2021 — traditional Chinese medicine — general requirements of moxibustion devices. Available online at: <https://www.iso.org/standard/83343.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2021b). ISO 19609-1:2021 — traditional Chinese medicine — quality and safety of raw materials and finished products made with raw materials — Part 1: general requirements. Available online at: <https://www.iso.org/standard/70976.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2021c). ISO 19609-2:2021 — traditional Chinese medicine — quality and safety of raw materials and finished products made with raw materials — Part 2: Identity testing of constituents of herbal origin. Available online at: <https://www.iso.org/standard/71152.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2021d). ISO 22466:2021 — traditional Chinese medicine — Laser acupoint devices. Available online at: <https://www.iso.org/standard/73287.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2021e). ISO 22467:2021 — traditional Chinese medicine — Determination of microorganisms in natural products. Available online at: <https://www.iso.org/standard/73288.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2021f). ISO 23190:2021 — traditional Chinese medicine — Determination of aristolochic acids in natural products by high-performance liquid chromatography (HPLC). Available online at: <https://www.iso.org/standard/74848.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2021g). ISO 23419:2021 — traditional Chinese medicine — general requirements for manufacturing procedures and quality assurance of granules. Available online at: <https://www.iso.org/standard/75513.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2021h). ISO 23723:2021 — traditional Chinese medicine — general requirements for herbal raw material and materia medica. Available online at: <https://www.iso.org/standard/76765.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2021i). ISO 23959:2021 — traditional Chinese medicine — *Glehnia littoralis* root. Available online at: <https://www.iso.org/standard/77466.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2021j). ISO 23961-1:2021 — traditional Chinese medicine — vocabulary for diagnostics — Part 1: tongue. Available online at: <https://www.iso.org/standard/77468.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2021k). ISO 23961-2:2021 — traditional Chinese medicine — vocabulary for diagnostics — Part 2: pulse. Available online at: <https://www.iso.org/standard/77470.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2021l). ISO 23962:2021 — traditional Chinese medicine — processed *Aconitum carmichaelii* lateral root. Available online at: <https://www.iso.org/standard/77469.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2021m). ISO 23972:2021 — traditional Chinese medicine — *Zingiber officinale* rhizome. Available online at: <https://www.iso.org/standard/77486.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2022a). ISO 4154:2022 — traditional Chinese medicine — *Sinomenium acutum* stem. Available online at: <https://www.iso.org/standard/80121.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2022b). ISO 4754:2022 — traditional Chinese medicine — Fermented cordyceps powder. Available online at: <https://www.iso.org/standard/80260.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2022c). ISO 5227:2022 — traditional Chinese medicine — safety controls for cupping devices. Available online at: <https://www.iso.org/standard/81034.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2022d). ISO 18665:2022 — traditional Chinese medicine — herbal decoction apparatus. Available online at: <https://www.iso.org/standard/83597.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2022e). ISO 19609-3:2022 — traditional Chinese medicine — quality and safety of raw materials and finished products made with raw materials — Part 3: testing for contaminants. Available online at: <https://www.iso.org/standard/78163.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2022f). ISO 19609-4:2022 — traditional Chinese medicine — quality and safety of raw materials and finished products made with raw materials — Part 4: testing for preservatives and unwanted compounds. Available online at: <https://www.iso.org/standard/78164.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2022g). ISO 22585:2022 — traditional Chinese medicine — *Codonopsis pilosula* root. Available online at: <https://www.iso.org/standard/73508.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2022h). ISO 22586:2022 — traditional Chinese medicine — *Paeonia lactiflora* root — white peony root. Available online at: <https://www.iso.org/standard/73509.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2022i). ISO 23956:2022 — traditional Chinese medicine — Determination of benzopyrene in processed natural products. Available online at: <https://www.iso.org/standard/77463.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2022j). ISO 23958-1:2022 — traditional Chinese medicine — Dermal needles for single use — Part 1: Tapping-type. Available online at: <https://www.iso.org/standard/77465.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2022k). ISO 23958-2:2022 — traditional Chinese medicine — Dermal needles for single use — Part 2: roller-type. Available online at: <https://www.iso.org/standard/77471.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2022l). ISO 23963-1:2022 — traditional Chinese medicine — requirements for process traceability systems in Chinese materia medica and decoction pieces — Part 1: components. Available online at: <https://www.iso.org/standard/77472.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2022m). ISO 23963-2:2022 — traditional Chinese medicine — requirements for process traceability system of Chinese materia medica and decoction pieces — Part 2: Electronic labelling. Available online at: <https://www.iso.org/standard/77478.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2022n). ISO 23964:2022 — traditional Chinese medicine — *Saposhnikovia divaricata* root and rhizome. Available online at: <https://www.iso.org/standard/77473.html> (Accessed October 12, 2025).

International Organization for Standardization (2022o). ISO 23965:2022 — traditional Chinese medicine — *Bupleurum chinense*, *Bupleurum scorzoniferifolium* and *Bupleurum falcatum* root. Available online at: <https://www.iso.org/standard/77474.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2022p). ISO 24571:2022 — traditional Chinese medicine — general requirements for the basic safety and essential performance of electro-acupuncture stimulators. Available online at: <https://www.iso.org/standard/71496.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2022q). ISO/TS 5118:2022 — health informatics — categorical structure of representation for evaluation of clinical practice guidelines of traditional Chinese medicine. Available online at: <https://www.iso.org/standard/81366.html> (Accessed October 12, 2025).

International Organization for Standardization (2022r). ISO/TS 5346:2022 — health informatics — categorical structure for representation of traditional Chinese medicine clinical decision support system. Available online at: <https://www.iso.org/standard/81136.html> (Accessed October 12, 2025).

International Organization for Standardization (2022s). ISO/TS 5568:2022 — health informatics — traditional Chinese medicine — labelling metadata of human biological sample information. Available online at: <https://www.iso.org/standard/81367.html> (Accessed October 12, 2025).

International Organization for Standardization (2022t). ISO/TS 6304:2022 — traditional Chinese medicine — categorical structure for disorders. Available online at: <https://www.iso.org/standard/82173.html?browse=tc> (Accessed October 12, 2025).

International Organization for Standardization (2022u). ISO/TS 16843-6:2022 Health informatics — Categorical structures for representation of acupuncture Part 6: acupuncture effects. Available online at: <https://www.iso.org/standard/81368.html> (Accessed October 12, 2025).

- International Organization for Standardization (2023a). ISO 4564:2023 — traditional Chinese medicine — *Scutellaria baicalensis* root. Available online at: <https://www.iso.org/standard/80122.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2023b). ISO 4904:2023 — traditional Chinese medicine — Inner pack of decoction pieces. Available online at: <https://www.iso.org/standard/80478.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2023c). ISO 5228:2023 — traditional Chinese medicine — *Rheum palmatum*, *Rheum tanguticum* and *Rheum officinale* root and rhizome. Available online at: <https://www.iso.org/standard/82920.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2023d). ISO 7177:2023 — traditional Chinese medicine — *Coptis chinensis* and *Coptis japonica* rhizome. Available online at: <https://www.iso.org/standard/82681.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2023e). ISO 7450:2023 — traditional Chinese medicine — *Pinellia ternata* tuber. Available online at: <https://www.iso.org/standard/82804.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2023f). ISO 9306:2023 — traditional Chinese medicine — *Ephedra sinica*, *Ephedra intermedia* and *Ephedra equisetina* herbaceous stem. Available online at: <https://www.iso.org/standard/83441.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2023g). ISO 20759:2023 — traditional Chinese medicine — *Artemisia argyi* leaf. Available online at: <https://www.iso.org/standard/87216.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2023h). ISO 22587:2023 — traditional Chinese medicine — Acupoint magnetotherapy plasters for single use. Available online at: <https://www.iso.org/standard/73510.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2023i). ISO/TR 4421:2023 health informatics — Introduction to ayurveda informatics. Available online at: <https://www.iso.org/standard/79933.html> (Accessed October 12, 2025).
- International Organization for Standardization (2023j). ISO/TS 5044:2023 — health informatics — information model for quality control of traditional Chinese medicinal products. Available online at: <https://www.iso.org/standard/80611.html> (Accessed October 12, 2025).
- International Organization for Standardization (2023k). ISO/TS 13126:2023 — traditional Chinese medicine — Determination of ochratoxin A in natural products by liquid chromatography coupled with fluorescence detector. Available online at: <https://www.iso.org/standard/84286.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2024a). ISO 5076:2024 — traditional Chinese medicine — *Angelica dahurica* root. Available online at: <https://www.iso.org/standard/84374.html> (Accessed October 12, 2025).
- International Organization for Standardization (2024b). ISO 5471:2024 — traditional Chinese medicine — *Carthamus tinctorius* flower. Available online at: <https://www.iso.org/standard/86191.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2024c). ISO 6559:2024 — traditional Chinese medicine — sterile three-edge needle for single use. Available online at: <https://www.iso.org/standard/82320.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2024d). ISO 6904:2024 — traditional Chinese Medicine — general requirements for the ultrafine powder of herbs. Available online at: <https://www.iso.org/standard/82431.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2024e). ISO 8071:2024 — traditional Chinese medicine — *Ligusticum chuansiong* rhizome. Available online at: <https://www.iso.org/standard/82991.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2024f). ISO 8284:2024 — traditional Chinese medicine — simplified accelerated stress simulation methods. Available online at: <https://www.iso.org/standard/83114.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2024g). ISO 8959:2024 — traditional Chinese medicine — *Eucommia ulmoides* stem bark. Available online at: <https://www.iso.org/standard/83422.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2024h). ISO 9109:2024 — traditional Chinese medicine — *Rehmannia glutinosa* root. Available online at: <https://www.iso.org/standard/83424.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2024i). ISO 9299:2024 — traditional Chinese medicine — *Curcuma longa* rhizome. Available online at: <https://www.iso.org/standard/83440.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2024j). ISO 9319:2024 — traditional Chinese medicine — *Poria cocos* sclerotium. Available online at: <https://www.iso.org/standard/83442.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2024k). ISO 13615:2024 — traditional Chinese medicine — *Atractylodes macrocephala* rhizome. Available online at: <https://www.iso.org/standard/84388.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2024l). ISO 13619:2024 — traditional Chinese medicine — *Gardenia jasminoides* fruit. Available online at: <https://www.iso.org/standard/84389.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2024m). ISO 19025:2024 — traditional Chinese medicine — *Glycyrrhiza uralensis*, *Glycyrrhiza inflata*, and *Glycyrrhiza glabra* root and rhizome. Available online at: <https://www.iso.org/standard/85721.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2024n). ISO/TR 18986:2024 — traditional Chinese medicine — report on the global industry and standardization development of *Panax ginseng*. Available online at: <https://www.iso.org/standard/85594.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2024o). ISO/TS 6204:2024 health informatics — Categorical structures for representation of ayurvedic medicinal water — decocting process in ayurveda. Available online at: <https://www.iso.org/standard/82110.html> (Accessed October 12, 2025).
- International Organization for Standardization (2024p). ISO/TS 6818:2024 — traditional Chinese medicine — test method for moxa floss quality — Concentration of waste particles. Available online at: <https://www.iso.org/standard/82372.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2024q). ISO/TS 23961-3:2024 — traditional Chinese medicine — vocabulary for diagnostics — Part 3: Abdomen. Available online at: <https://www.iso.org/standard/82571.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2025a). ISO 5106:2025 — traditional Chinese medicine — *Polygala tenuifolia* and *Polygala sibirica* root. Available online at: <https://www.iso.org/standard/84375.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2025b). ISO 19842:2025 — traditional Chinese medicine — *Dioscorea opposita* rhizome. Available online at: <https://www.iso.org/standard/85985.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2025c). ISO 19851:2025 — traditional Chinese medicine — *Cinnamomum cassia* branch. Available online at: <https://www.iso.org/standard/85986.html?browse=tc> (Accessed October 12, 2025).
- International Organization for Standardization (2025d). ISO/TR 23975:2025 — traditional Chinese medicine — priority list of single herbal medicines for developing standards. Available online at: <https://www.iso.org/standard/86397.html?browse=tc> (Accessed October 12, 2025).
- Kahumba, J., Rasamiravaka, T., Okusa Ndjolo, P., Bakari, S. A., Bizumukama, L., Kiendrebeogo, M., et al. (2015). Traditional African medicine: from ancestral knowledge to a modern integrated future. *Science* 350 (6259 Suppl. 1), S61–S63.
- Kelly, W., Arellano, F., Barnes, J., Bergman, U., Edwards, R., Fernandez, A., et al. (2009). Guidelines for submitting adverse event reports for publication. *Therapie* 64 (4), 289–294. doi:10.2515/therapie/2009041
- Kwakkenbos, L., Imran, M., McCall, S. J., McCord, K. A., Fröbert, O., Hemkens, L. G., et al. (2021). CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. *BMJ* 373, n857. doi:10.1136/bmj.n857
- Lachat, C., Hawwash, D., Ocké, M. C., Berg, C., Forsum, E., Hörnell, A., et al. (2016). Strengthening the reporting of Observational studies in Epidemiology—Nutritional Epidemiology (STROBE-nut): an extension of the STROBE statement. *PLoS Med.* 13 (6), e1002036. doi:10.1371/journal.pmed.1002036
- Lam, C. S., Au, K. Y., Hung, H. Y., Chou, H. W., Leung, A. W. K., Li, C. K., et al. (2022). Integrating complementary medicine into the care of Childhood cancer survivors: a brief report on the preliminary framework and implementation of an educational Program. *Front. Rehabil. Sci.* 3, 897677. doi:10.3389/fresc.2022.897677
- Li, J., Hu, J. Y., Zhai, J. B., Niu, J. Q., Kwong, J. S. W., Ge, L., et al. (2019). CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): recommendations, explanation and elaboration. *Complement. Ther. Med.* 46, 180–188. doi:10.1016/j.ctim.2019.08.014
- Li, X., Huang, L., Wang, L., Jin, X., Zhou, Q., Ma, Y., et al. (2024). The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM. *Pharmacol. Res.* 199, 107015. doi:10.1016/j.phrs.2023.107015
- Liu, J. P., Manheimer, E., and Yang, M. (2005). Herbal medicines for treating HIV infection and AIDS. *Cochrane Database Syst. Rev.* 2005 (3), Cd003937. doi:10.1002/14651858.CD003937.pub2
- Ma, P., Liu, X., Liu, Z., Guo, Y., Zhou, K., Bian, Z., et al. (2023). The SHARE: SHam acupuncture REporting guidelines and a checklist in clinical trials. *J. Evid. Based Med.* 16 (4), 428–431. doi:10.1111/jebm.12560
- MacPherson, H., White, A., Cummings, M., Jobst, K., Rose, K., and Niemtzwow, R. (2001). Standards for reporting interventions in controlled trials of acupuncture: the STRICTA recommendations. *J. Altern. Complement. Med.* 9 (4), 246–249. doi:10.1054/ctim.2001.0488
- MacPherson, H., Altman, D. G., Hammerschlag, R., Youping, L., Taixiang, W., White, A., et al. (2010). Revised STandards for reporting interventions in clinical trials of acupuncture (STRICTA): extending the CONSORT statement. *J. Altern. Complement. Med.* 16 (10), ST-1–ST-14. doi:10.1089/acm.2010.1610
- Mao, J. J., Greenlee, H., Bao, T., Ismaila, N., and Bruera, E. (2022a). Integrative medicine for pain management in oncology: society for integrative oncology-ASCO guideline summary and Q&A. *JCO Oncol. Pract.* 19 (1), 45–48. doi:10.1200/OP.22.00622

- Mao, J. J., Ismaila, N., Bao, T., Barton, D., Ben-Arye, E., Garland, E. L., et al. (2022b). Integrative medicine for pain management in oncology: society for integrative oncology-ASCO guideline. *J. Clin. Oncol.* 40 (34), 3998–4024. doi:10.1200/JCO.22.01357
- McGowan, J., Straus, S., Moher, D., Langlois, E. V., O'Brien, K. K., Horsley, T., et al. (2020). Reporting scoping reviews-PRISMA ScR extension. *J. Clin. Epidemiol.* 123, 177–179. doi:10.1016/j.jclinepi.2020.03.016
- Moher, D., Schulz, K. F., Simera, I., and Altman, D. G. (2010). Guidance for developers of health research reporting guidelines. *PLoS Med.* 7 (2), e1000217. doi:10.1371/journal.pmed.1000217
- Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., et al. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst. Rev.* 4 (1), 1. doi:10.1186/2046-4053-4-1
- Munk, N., and Boulanger, K. (2014). Adaptation of the CARE guidelines for therapeutic massage and bodywork publications: efforts to improve the impact of case reports. *Int. J. Ther. Massage Bodyw.* 7 (3), 32–40. doi:10.3822/ijtm.v7i3.251
- Nahin, R. L., Rhee, A., and Stussman, B. (2024). Use of complementary health approaches overall and for pain management by US adults. *JAMA* 331 (7), 613–615. doi:10.1001/jama.2023.26775
- National Health Commission of the People's Republic of China (2003). Statistical Bulletin on the development of national health service in 2002 (2002年全国卫生事业发展情况统计公报). Beijing. Available online at: https://www.nhc.gov.cn/wjw/gongbolist_17.shtml (Accessed October 25, 2025).
- National Health Commission of the People's Republic of China (2024). Statistical Bulletin on the development of health care in China in 2023 (2023年我国卫生健康事业发展统计公报). Beijing. Available online at: <https://www.nhc.gov.cn/guihuaxs/c100133/202408/0c53d04ede9e4079aff912d71b5131c.shtml>.
- Ogrinc, G., Davies, L., Goodman, D., Batalden, P., Davidoff, F., and Stevens, D. (2016). SQUIRE 2.0 (Standards for Quality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. *BMJ Qual. Saf.* 25 (12), 986–992. doi:10.1136/bmjqs-2015-004411
- Olenina, N. G. (2025). Efficacy and safety of herbal medicinal products: registration requirements in the EAEU and other regions of the world. *Безопасность и риск фармакотерапии* 13 (1), 108–120. (Review). doi:10.30895/2312-7821-2025-13-1-108-120
- Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *PLoS Med.* 18 (3), e1003583. doi:10.1371/journal.pmed.1003583
- Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., et al. (2020). The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. *Br. J. Pharmacol.* 177 (16), 3617–3624. doi:10.1111/bph.15193
- Qaseem, A., Forland, F., Macbeth, F., Ollenschläger, G., Phillips, S., and van der Wees, P., et al. (2012). Guidelines international network: toward international standards for clinical practice guidelines. *Ann. Intern. Med.* 156 (7), 525–531. doi:10.7326/0003-4819-156-7-201204030-00009
- Rethlefsen, M. L., Kirtley, S., Waffenschmidt, S., Ayala, A. P., Moher, D., Page, M. J., et al. (2021). PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. *Syst. Rev.* 10 (1), 39. doi:10.1186/s13643-020-01542-z
- Rivera, D., Allkin, R., Obón, C., Alcaraz, F., Verpoorte, R., and Heinrich, M. (2014). What is in a name? The need for accurate scientific nomenclature for plants. *J. Ethnopharmacol.* 152 (3), 393–402. doi:10.1016/j.jep.2013.12.022
- Rizzo, R. R. N., Cashin, A. G., Wand, B. M., Ferraro, M. C., Sharma, S., Lee, H., et al. (2025). Non-pharmacological and non-surgical treatments for low back pain in adults: an overview of cochrane reviews. *Cochrane Database Syst. Rev.* 2025 (3). doi:10.1002/14651858.CD014691.pub2
- Rubio, I. T., Wyld, L., Marotti, L., Athanasiou, A., Regitnig, P., Catanuto, G., et al. (2024). European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO. *Eur. J. Surg. Oncol.* 50 (1), 107292. doi:10.1016/j.ejso.2023.107292
- Schünemann, H. J., Okwen, P., Akl, E., Chrisp, P., Dahm, P., Falck-Ytter, Y., et al. (2025). An international guideline training and certification programme. *Bull. World Health Organ* 103, 281–284. doi:10.2471/BLT.24.291587
- Society for Acupuncture Research (NA). SAR's evidence based assessments. Available online at: <https://www.acupunctureresearch.org/evidence-based-assessment-library> (Accessed April 13, 2025).
- Society for Acupuncture Research (2011–2016). White papers by SAR. Available online at: <https://www.acupunctureresearch.org/white-papers> (Accessed August 27, 2025).
- Society for Integrative Oncology (2020). Conflict of interest policy implementation for clinical practice guidelines of the society for integrative oncology. Available online at: <https://integrativeonc.org/wp-content/uploads/2023/09/sio-conflict-interest-policy-implementation-clinical-practice-guidelines.pdf>.
- Song, Y., Alonso-Coello, P., Ballesteros, M., Cluzeau, F., Vernooij, R. W. M., Arayssi, T., et al. (2022). A reporting tool for adapted guidelines in health care: the RIGHT-Ad+pt checklist. *Ann. Intern. Med.* 175 (5), 710–719. doi:10.7326/m21-4352
- Sousa-Pinto, B., Marques-Cruz, M., Neumann, I., Chi, Y., Nowak, A. J., Reinap, M., et al. (2025). Guidelines international network: principles for use of artificial intelligence in the health guideline enterprise. *Ann. Intern. Med.* 178 (3), 408–415. doi:10.7326/annals-24-02338
- Stewart, L. A., Clarke, M., Rovers, M., Riley, R. D., Simmonds, M., Stewart, G., et al. (2015). Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. *JAMA* 313 (16), 1657–1665. doi:10.1001/jama.2015.3656
- Tang, C., Lu, L., Duan, Y., Zhang, Y., Zhou, Q., Luo, X., et al. (2019). Developing an extension of the RIGHT statement for clinical practice guidelines on acupuncture: RIGHT for acupuncture – a protocol. *Eur. J. Integr. Med.* 29: 100908. doi:10.1016/j.eujim.2019.04.002
- Tang, C., Duan, Y., Zhang, Y., Zhang, Y., Chen, Z., Tang, X., et al. (2021). RIGHT for acupuncture: an extension of the RIGHT statement for clinical practice guidelines on acupuncture. *J. Clin. Epidemiol.* 139, 330–339. doi:10.1016/j.jclinepi.2021.05.021
- The European Scientific Cooperative on Phytotherapy (2003). Monographs. Available online at: <https://www.escop.com/escop-products/publications/> (Accessed April 13, 2025).
- The European Scientific Cooperative on Phytotherapy (2009). Monographs, 2nd Edition Supplement. Available online at: <https://www.escop.com/escop-products/publications/> (Accessed April 13, 2025).
- The Gulf Health Council (2022). The GCC regulations for products classification. Available online at: <https://www.sfda.gov.sa/system/files/2022/ProductsClassification.pdf> (Accessed October 14, 2025).
- The Wildlife Trade Monitoring Network (2023). Guidelines for risk assessment in the Utilisation of medicinal Fauna and Flora. Available online at: https://www.traffic.org/site/assets/files/22315/guidelines_for_risk_assessment_in_the_utilisation_of_medicinal_fauna_and_flora_english_version.pdf.
- Tricco, A. C., Lillie, E., Zarin, W., O'Brien, K. K., Colquhoun, H., Levac, D., et al. (2018). PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Ann. Intern. Med.* 169 (7), 467–473. doi:10.7326/m18-0850
- von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Götzsche, P. C., Vandenbroucke, J. P., et al. (2007). The strengthening of reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann. Intern. Med.* 147 (8), 573–577. doi:10.7326/0003-4819-147-8-200710160-00010
- von Schoen-Angerer, T., Manchanda, R. K., Lloyd, I., Wardle, J., Szöke, J., Benevides, I., et al. (2023). Traditional, complementary and integrative healthcare: global stakeholder perspective on WHO's current and future strategy. *BMJ Glob. Health* 8 (12), e013150. doi:10.1136/bmjgh-2023-013150
- Wang, X., Chen, Y., Liu, Y., Yao, L., Estill, J., Bian, Z., et al. (2019). Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. *BMC Complement. Altern. Med.* 19 (1), 208. doi:10.1186/s12906-019-2624-3
- Wang, X., Ma, Y., Xu, Q., Shikov, A. N., Pozharitskaya, O. N., Flisyuk, E. V., et al. (2023). Flavonoids and saponins: what have we got or missed? *Phytomedicine* 109, 154580. doi:10.1016/j.phymed.2022.154580
- Wang, Z., Zhang, D., Inuzuka, H., and Wei, W. (2025). PROTAC technology for prostate cancer treatment. *Acta Mater. Medica* 4 (1), 99–121. doi:10.15212/AMM-2024-0075
- Ward, L., Nault, D., Cramer, H., and Moonaz, S. (2022). Development of the CLARIFY (CheckList stAndardising the reporting of interventions for yoga) guidelines: a Delphi study. *BMJ Open* 12 (1), e054585. doi:10.1136/bmjopen-2021-054585
- Welch, V., Petticrew, M., Tugwell, P., Moher, D., O'Neill, J., Waters, E., et al. (2012). PRISMA-equity 2012 extension: reporting guidelines for systematic reviews with a focus on health equity. *PLoS Med.* 9 (10), e1001333. doi:10.1371/journal.pmed.1001333
- Whaley, A. O., Whaley, A. K., Kovaleva, E. L., Frolova, L. N., Orlova, A. A., Luzhanin, V. G., et al. (2023). The standardization of officinal medicinal plants used in the Eurasian Economic Union: comparison with other pharmacopoeias. *Phytochem. Rev.* 23 (2), 349–419. doi:10.1007/s11101-023-09887-8
- Witt, C. M., Aickin, M., Cherkin, D., Che, C. T., Elder, C., Flower, A., et al. (2014). Effectiveness guidance document (EGD) for Chinese medicine trials: a consensus document. *Trials* 15 (1), 169. doi:10.1186/1745-6215-15-169
- World Federation of Acupuncture-moxibustion Societies (2008). International standard Chinese-English: basic nomenclature of Chinese medicine. Available online at: <https://dl.icdst.org/pdfs/files3/5312e1ec2e71b79baa32d03dfc9928d2.pdf> (Accessed October 12, 2025).
- World Federation of Acupuncture-moxibustion Societies (2023a). WFAS 005.1—2023 General requirements for the risk control in the safe use of acupuncture. Available online at: <https://wfas.kejie.org.cn/download/1559/WFAS+005.1%E2%80%942023+General+requirements+for+the+risk+control+in+the+safe+use+of+acupuncture.pdf> (Accessed October 12, 2025).
- World Federation of Acupuncture-moxibustion Societies (2023b). WFAS 006.1—2023 Technical benchmark of acupuncture and moxibustion—general rules for drafting. Available online at: <https://wfas.kejie.org.cn/download/1560/WFAS+006.1%E2%80%942023+Technical+benchmark+of+acupuncture+and+moxibustion%E2%80%942023+General+rules+for+drafting.pdf> (Accessed October 12, 2025).
- World Federation of Acupuncture-moxibustion Societies (2023c). WFAS 006.2—2023 Technical benchmark of acupuncture and moxibustion—Scalp

acupuncture. Available online at: <https://wfas.kejie.org.cn/download/1561/WFAS+006.2%E2%80%942023+Technical+benchmark+of+acupuncture+and+moxibustion%E2%80%9494Scalp+acupuncture.pdf> (Accessed October 12, 2025).

World Federation of Acupuncture-moxibustion Societies (2023d). WFAS 006.4—2023 Technical benchmark of acupuncture and moxibustion—guasha. Available online at: <https://wfas.kejie.org.cn/download/1563/WFAS+006.4%E2%80%942023+Technical+benchmark+of+acupuncture+and+moxibustion%E2%80%9494Guasha.pdf> (Accessed October 12, 2025).

World Federation of Acupuncture-moxibustion Societies (2023e). WFAS 006.5—2023 Technical benchmark of acupuncture and moxibustion—Periocular acupuncture. Available online at: <https://wfas.kejie.org.cn/download/1564/WFAS+006.5%E2%80%942023+Technical+benchmark+of+acupuncture+and+moxibustion%E2%80%9494Periocular+acupuncture.pdf> (Accessed October 12, 2025).

World Federation of Acupuncture-moxibustion Societies (2023f). WFAS 006.6—2023 Technical benchmark of acupuncture and moxibustion—Electroacupuncture. Available online at: <https://wfas.kejie.org.cn/download/1565/WFAS+006.6%E2%80%942023+Technical+benchmark+of+acupuncture+and+moxibustion%E2%80%9494Electroacupuncture.pdf> (Accessed October 12, 2025).

World Federation of Acupuncture-moxibustion Societies (2023g). WFAS 006.7—2023 Technical benchmark of acupuncture and moxibustion—Filiform needle. Available online at: <https://wfas.kejie.org.cn/download/1566/WFAS+006.7%E2%80%942023+Technical+benchmark+of+acupuncture+and+moxibustion%E2%80%9494Filiform+needle.pdf> (Accessed October 12, 2025).

World Federation of Acupuncture-moxibustion Societies (2023h). WFAS 006.8—2023 Technical benchmark of acupuncture and moxibustion—moxibustion manipulations. Available online at: <https://wfas.kejie.org.cn/download/1567/WFAS+006.8%E2%80%942023+Technical+benchmark+of+acupuncture+and+moxibustion%E2%80%9494Moxibustion+manipulations.pdf> (Accessed October 12, 2025).

World Federation of Acupuncture-moxibustion Societies (2023i). WFAS 006.9—2023 Technical benchmark of acupuncture and moxibustion—cupping. Available online at: <https://wfas.kejie.org.cn/download/1568/WFAS+006.9%E2%80%942023+Technical+benchmark+of+acupuncture+and+moxibustion%E2%80%9494Cupping.pdf> (Accessed October 12, 2025).

World Federation of Acupuncture-moxibustion Societies (2023j). WFAS 007.1—2023 Norms for formulation and evaluation of the clinical practice guidelines of acupuncture and moxibustion. Available online at: <https://wfas.kejie.org.cn/download/1569/WFAS+007.1%E2%80%942023+Norms+for+formulation+and+evaluation+of+the+clinical+practice+guidelines+of+acupuncture+and+moxibustion.pdf> (Accessed October 12, 2025).

World Federation of Acupuncture-moxibustion Societies (2023k). WFAS 007.2—2023 Clinical guideline on acupuncture and moxibustion—Smoking cessation. Available online at: <https://wfas.kejie.org.cn/download/1570/WFAS+007.2%E2%80%942023+Clinical+guideline+on+acupuncture+and+moxibustion%E2%80%9494Smoking+cessation.pdf> (Accessed October 12, 2025).

World Federation of Acupuncture-moxibustion Societies (2023l). WFAS 007.3—2023 Clinical guideline on acupuncture and moxibustion—adult depressive disorder (mild - moderate degree). Available online at: <https://wfas.kejie.org.cn/download/1571/WFAS+007.3%E2%80%942023+Clinical+guideline+on+acupuncture+and+moxibustion%E2%80%9494Adult+depressive+disorder+%28mild+-+moderate+degree%29.pdf> (Accessed October 12, 2025).

World Federation of Acupuncture-moxibustion Societies (2023m). WFAS 007.4—2023 Clinical guideline on acupuncture and moxibustion—Chronic constipation. Available online at: <https://wfas.kejie.org.cn/download/1572/WFAS+007.4%E2%80%942023+Clinical+guideline+on+acupuncture+and+moxibustion%E2%80%9494Chronic+constipation.pdf> (Accessed October 12, 2025).

World Federation of Acupuncture-moxibustion Societies (2023n). WFAS 007.5—2023 Clinical guideline on acupuncture and moxibustion—Allergic rhinitis. Available online at: <https://wfas.kejie.org.cn/download/1574/WFAS+007.5%E2%80%942023+Clinical+guideline+on+acupuncture+and+moxibustion%E2%80%9494Allergic+rhinitis.pdf> (Accessed October 12, 2025).

World Federation of Acupuncture-moxibustion Societies (2023o). WFAS 007.7—2023 Clinical guideline on acupuncture and moxibustion—non-specific low back pain. Available online at: <https://wfas.kejie.org.cn/download/1576/WFAS+007.7%E2%80%942023+Clinical+guideline+on+acupuncture+and+moxibustion%E2%80%9494Non-specific+low+back+pain.pdf> (Accessed October 12, 2025).

World Federation of Acupuncture-moxibustion Societies (2023p). WFAS 007.8—2023 Clinical guideline on acupuncture and moxibustion—Migraine. Available online at: <https://wfas.kejie.org.cn/download/1577/WFAS+007.8%E2%80%942023+Clinical+guideline+on+acupuncture+and+moxibustion%E2%80%9494Migraine.pdf> (Accessed October 12, 2025).

World Federation of Acupuncture-moxibustion Societies (2023q). WFAS 007.9—2023 Clinical guideline on acupuncture and moxibustion—Gastroesophageal reflux disease (GERD). Available online at: <https://wfas.kejie.org.cn/download/1578/WFAS+007.9%E2%80%942023+Clinical+guideline+on+acupuncture+and+moxibustion%E2%80%9494Gastroesophageal+reflux+disease+%28GERD%29.pdf> (Accessed October 12, 2025).

World Federation of Acupuncture-moxibustion Societies (2023r). WFAS 008.1—2023 Guideline for registry of acupuncture-moxibustion clinical research. Available online at: <https://wfas.kejie.org.cn/download/1579/WFAS+008.1%E2%80%942023+Guideline+for+registry+of+acupuncture-moxibustion+clinical+research.pdf> (Accessed October 12, 2025).

World Federation of Acupuncture-moxibustion Societies (2023s). WFAS 009.1—2023 Good clinical practice of acupuncture-moxibustion research. Available online at: <https://wfas.kejie.org.cn/download/1580/WFAS+009.1%E2%80%942023+Good+clinical+practice+of+acupuncture-moxibustion+research.pdf> (Accessed October 12, 2025).

World Federation of Acupuncture-moxibustion Societies. (2024). Clinical practice guideline for acupuncture and moxibustion: Female urinary incontinence. doi:10.1016/j.joim.2024.04.002

World Federation of Chinese Medicine Societies (2022-2026). International standards (in Chinese). Available online at: <https://www.wfcm.org/list/52.html> (Accessed April 13, 2025).

World Health Organization (1991). Guidelines for the assessment of herbal medicines. Available online at: <https://iris.who.int/server/api/core/bitstreams/872d60df-c492-4ee6-8984-de8b0aa2ee60/content>.

World Health Organization (2000a). General guidelines for methodologies on research and evaluation of traditional medicine. Available online at: <https://www.who.int/publications/i/item/9789241506090> (Accessed October 12, 2025).

World Health Organization (2000b). Resolution promoting the role of traditional medicine in health systems: a strategy for the African region. Ouagadougou, Burkina Faso 2. Available online at: https://iris.who.int/bitstream/handle/10665/95456/AFRC50_R3.pdf (Accessed October 12, 2025).

World Health Organization (2002a). WHO traditional medicine strategy 2002-2005, 74. Geneva, Switzerland. Available online at: <https://www.who.int/publications/i/item/WHO-EDM-TRM-2002.1> (Accessed October 13, 2025).

World Health Organization (2002b). Regional strategy for traditional medicine in the Western Pacific. Geneva. Available online at: <https://www.who.int/publications/i/item/9290610115> (Accessed October 12, 2025).

World Health Organization. (2003a). Developing regional guidelines on minimum requirements for the registration of herbal medicinal products. Report of a Workshop, Abu Dhabi, United Arab Emirates, 7-9 June 2003. Available online at: <https://iris.who.int/handle/10665/255076>. Accessed October 12, 2025.

World Health Organization (2003b). Guidelines for the regulation of herbal medicines in the South-East Asia region. Geneva. Available online at: <https://www.who.int/publications/i/item/SEA-Trad-Med-82> (Accessed October 12, 2025).

World Health Organization. (2003c). WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants. Geneva. Available online at: <https://www.who.int/publications/i/item/9241546271> (Accessed October 12, 2025).

World Health Organization (2003d). WHO medicines strategy 2004-2007: countries at the core. Available online at: https://iris.who.int/bitstream/handle/10665/68514/WHO_EDM_2004.2.pdf?sequence=1&isAllowed=y (Accessed October 12, 2025).

World Health Organization (2004a). WHO guidelines on developing consumer information on proper use of traditional, complementary and alternative medicine. Available online at: <https://iris.who.int/handle/10665/42957?locale-attribute=en&> (Accessed October 12, 2025).

World Health Organization (2004b). WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems. Available online at: <https://www.who.int/publications/i/item/9241592214> (Accessed October 12, 2025).

World Health Organization (2007a). The traditional medicine components of the WHO Medicines Strategy 2008-2013. Available online at: https://iris.who.int/bitstream/handle/10665/70301/WHO_EMP_2009.1_eng.pdf?sequence=1 (Accessed October 12, 2025).

World Health Organization (2007b). WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues. Geneva. Available online at: <https://www.who.int/publications/i/item/9789241594448> (Accessed October 12, 2025).

World Health Organization (2007c). WHO guidelines on good manufacturing practices (GMP) for herbal medicines. Available online at: <https://www.who.int/publications/i/item/9789241547161> (Accessed October 12, 2025).

World Health Organization (2007d). WHO international standard terminologies on traditional medicine in the Western Pacific region. Available online at: <https://iris.who.int/handle/10665/206952> (Accessed October 12, 2025).

World Health Organization (2008). WHO standard acupuncture point locations in the Western Pacific region. Available online at: <https://iris.who.int/handle/10665/353407?locale-attribute=en&> (Accessed October 12, 2025).

World Health Organization (2009). International clinical trials registry platform (ICTRP)-WHO registry criteria (version 2.1, April 2009). Available online at: <https://www.who.int/tools/clinical-trials-registry-platform/network/registry-criteria> (Accessed October 12, 2025).

World Health Organization (2011a). Annex 6 WHO good manufacturing practices for sterile pharmaceutical products. Geneva. Available online at: https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/production/trs961-annex6-gmp-sterile-pharmaceutical-products.pdf?sfvrsn=61682f0c_0%22 (Accessed October 12, 2025).

- World Health Organization (2011b). Quality control methods for herbal materials. Geneva. Available online at: <https://www.who.int/publications/i/item/9789241500739> (Accessed October 12, 2025).
- World Health Organization (2012a). Operational guidance: information needed to support clinical trials of herbal products. Geneva. Available online at: <https://www.who.int/publications/i/item/TDR-GEN-Guidance-05.1> (Accessed October 12, 2025).
- World Health Organization (2012b). The regional strategy for traditional medicine in the Western Pacific (2011–2020). Available online at: <https://www.who.int/publications/i/item/9789290615590> (Accessed October 12, 2025).
- World Health Organization (2013). WHO Traditional medicine strategy 2014–2023, 78. Geneva, Switzerland. Available online at: <https://iris.who.int/server/api/core/bitstreams/16362a42-6583-4601-a7da-d0ed6bc39108/content> (Accessed October 12, 2025).
- World Health Organization (2016a). Fiftieth report of the WHO Expert Committee on specifications for pharmaceutical preparations. Available online at: <https://iris.who.int/handle/10665/255338?locale-attribute=en&> (Accessed October 12, 2025).
- World Health Organization. (2016b). Guidelines for accurate and transparent health Estimates reporting. Geneva: doi:10.1016/s0140-6736(16)30388-9
- World Health Organization (2017). TRS 1003 - 51st report of the WHO expert committee on specifications for pharmaceutical preparations. Available online at: <https://www.who.int/publications/i/item/9789241210034> (Accessed October 12, 2025).
- World Health Organization (2023). Technical products (TPs) on norms and standards. Geneva. Available online at: <https://www.who.int/our-work/technical-products> (Accessed October 12, 2025).
- World Health Organization (2018a). Fifty-second report of the WHO expert committee on specifications for pharmaceutical preparations. Available online at: <https://iris.who.int/handle/10665/272452> (Accessed October 12, 2025).
- World Health Organization (2018b). International standards for clinical trial registries. Available online at: <https://iris.who.int/bitstream/handle/10665/274994/9789241514743-eng.pdf?sequence=1> (Accessed October 12, 2025).
- World Health Organization (2019a). Good storage and distribution practices for medical products. Geneva. Available online at: <https://iris.who.int/handle/10665/330887?locale-attribute=en&> (Accessed October 12, 2025).
- World Health Organization (2019b). WHO global report on traditional and complementary medicine 2019. Available online at: <https://www.who.int/publications/i/item/978924151536> (Accessed October 12, 2025).
- World Health Organization (2020a). Quality control methods for medicinal plant materials Available online at: <https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/quality-control/quality-control-methods-for-medicinal-plant-materials.pdf> (Accessed October 12, 2025).
- World Health Organization (2020b). TRS 1025 - 54th report of the WHO expert Committee on specifications for pharmaceutical preparations. Available online at: <https://iris.who.int/bitstream/handle/10665/331814/9789240001824-eng.pdf?sequence=1> (Accessed October 12, 2025).
- World Health Organization (2020c). WHO benchmarks for the training of acupuncture. Available online at: <https://www.who.int/publications/i/item/9789240017962> (Accessed October 12, 2025).
- World Health Organization (2022a). TRS 1044 - 56th report of the WHO expert committee on specifications for pharmaceutical preparations. Available online at: <https://iris.who.int/bitstream/handle/10665/365397/9789240063822-eng.pdf?sequence=1> (Accessed October 12, 2025).
- World Health Organization (2022b). WHO international standard terminologies on traditional Chinese medicine. Available online at: <https://iris.who.int/bitstream/handle/10665/352306/9789240042322-eng.pdf?sequence=1> (Accessed October 12, 2025).
- World Health Organization (2023a). Integrating traditional and complementary medicine into health systems: social, economic and health considerations. Available online at: https://cdn.who.int/media/docs/default-source/universal-health-coverage/who-uhl-technical-brief-traditional-complementary-medicine.pdf?sfvrsn=956b9693_3&download=true (Accessed October 12, 2025).
- World Health Organization (2023b). A map of systematic reviews on traditional, complementary, and integrative medicine (TCIM) 2018–2022. Available online at: https://terrance.who.int/internet/tmc/gap_map_traditional_medicine.html.
- World Health Organization (2024a). Clinical practice guidelines for influenza. Available online at: <https://iris.who.int/bitstream/handle/10665/378872/9789240097759-eng.pdf?sequence=1> (Accessed October 12, 2025).
- World Health Organization (2024b). Guidance for best practices for clinical trials. Geneva. Available online at: <https://www.who.int/publications/i/item/9789240097711> (Accessed October 12, 2025).
- World Health Organization (2024c). Guidelines: production. Geneva. Available online at: <https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/guidelines/production> (Accessed October 12, 2025).
- World Health Organization (2025a). Draft global traditional medicine strategy 2025–2034. Geneva, Switzerland. Available online at: https://apps.who.int/gb/ebwha/pdf_files/WHA78/A78_4Add1-en.pdf (Accessed October 12, 2025).
- World Health Organization (2025b). Mapping the application of artificial intelligence in traditional medicine: technical brief. Geneva. Available online at: <https://iris.who.int/server/api/core/bitstreams/6779075c-c354-4a76-acc-4ae635dee436/content> (Accessed October 12, 2025).
- World Health Organization (2026a). Guidelines: development. Available online at: <https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/guidelines/development> (Accessed April 13, 2025).
- World Health Organization (2026b). Resolution promoting the role of traditional medicine in health systems: a strategy for the african region. *Ouagadougou, Burkina Faso* 2. Available online at: <https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/guidelines/distribution> (Accessed April 13, 2025).
- World Health Organization (2026c). Guidelines: inspections. Available online at: <https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/guidelines/inspections> (Accessed April 13, 2025).
- World Health Organization (2026d). Guidelines: Prequalification. Available online at: <https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/guidelines/prequalification> (Accessed April 13, 2025).
- World Health Organization (2026e). Guidelines: quality assurance. Available online at: <https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/guidelines/quality-assurance> (Accessed April 13, 2025).
- World Health Organization (2026f). Guidelines: quality control. Available online at: <https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/guidelines/quality-control> (Accessed April 13, 2025).
- Xie, R., Xia, Y., Chen, Y., Li, H., Shang, H., Kuang, X., et al. (2020). The RIGHT extension statement for traditional Chinese medicine: development, recommendations, and explanation. *Pharmacol. Res.* 160, 105178. doi:10.1016/j.phrs.2020.105178
- Xu, Q. (2023). WHO international standard terminologies on traditional Chinese medicine: use in context, creatively. *Integrat. Med. Nephrol. Androl.* 10 (2). doi:10.1097/imna-d-22-00029
- Xu, Q., Bauer, R., Hendry, B. M., Fan, T. P., Zhao, Z., Duez, P., et al. (2013). The quest for modernisation of traditional Chinese medicine. *BMC Complement. Altern. Med.* 13, 132. doi:10.1186/1472-6882-13-132
- Zhang, X., Tan, R., Lam, W. C., Cheng, C. W., Yao, L., Wang, X. Q., et al. (2020a). PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. *Syst. Rev.* 9 (1), 247. doi:10.1186/s13643-020-01502-7
- Zhang, X., Tan, R., Lam, W. C., Yao, L., Wang, X., Cheng, C. W., et al. (2020b). PRISMA (Preferred reporting items for systematic reviews and meta-analyses) extension for Chinese herbal medicines 2020 (PRISMA-CHM 2020). *Am. J. Chin. Med.* 48 (06), 1279–1313. doi:10.1142/S0192415X20500639
- Zhang, X., Tian, R., Lam, W. C., Duan, Y., Liu, F., Zhao, C., et al. (2020c). Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement. *Chin. Med.* 15, 10. doi:10.1186/s13020-020-0293-2
- Zhang, X., Liang, F., Lau, C. T., Chan, J. C., Wang, N., Deng, J., et al. (2023). Standards for reporting interventions in clinical trials of tuina/massage (STRICTOTM): extending the CONSORT statement. *J. Evid. Based Med.* 16 (1), 68–81. doi:10.1111/jebm.12522
- Zorzela, L., Loke, Y. K., Ioannidis, J. P., Golder, S., Santaguida, P., Altman, D. G., et al. (2016). PRISMA harms checklist: improving harms reporting in systematic reviews. *BMJ* 353, i2229. doi:10.1136/bmj.i2229

Glossary

AAPB	Association for Applied Psychophysiology and Biofeedback	PAHO	Pan American Health Organization
AI	Artificial Intelligence	PCC	Population, Concept and Context
AOAC	Association of Official Agricultural Chemists International	Ph. Eur.	European Pharmacopoeia
AU	African Union	SAR	Society for Acupuncture Research
CA	Comunidad Andina (<i>La Comunidad Andina</i>)	SIO	Society for Integrative Oncology
CIOMS	Council for International Organizations of Medical Sciences	SIOP	International Society of Paediatric Oncology
COPE	Committee on Publication Ethics guidelines	TCIM	Traditional, Complementary and Integrative Medicine
DTx	Digital Therapeutics Alliance	TCIMg	General IS/IGPG in the Broad Field of Traditional, Complementary and Integrative Medicine
EAEU	Eurasian Economic Union	TCM	Traditional Chinese Medicine
EDQM	European Directorate for the Quality of Medicines and HealthCare	TCMg	General IS/IGPG in the Field of Traditional Chinese Medicine
EMA/HMPC	European Medicines Agency/Committee on Herbal Medicinal Products	TRAFFIC	The long-term Vision of the Kunming-Montreal Global Biodiversity Framework
EQUATOR Network	Enhancing the QUAlity and Transparency Of health Research	WAHO	West African Health Organization
ESCOP	European Scientific Cooperative on Phytotherapy	WFAS	World Federation of Acupuncture-Moxibustion Societies
EUM	Estados Unidos Mexicanos	WFCMS	World Federation of Chinese Medicine Societies
EUSOMA	European Society of Breast Cancer Specialists	WHO	World Health Organization
GA	Society for Medicinal Plant and Natural Product Research		
GBIF	Global Biodiversity Information Facility		
GCRSR	Global Coalition for Regulatory Science Research		
GHC/GCC	The Gulf Health Council/The Gulf Cooperation Council		
GIN	Guidelines International Network		
GMP	Good Manufacturing Practices		
HIMSS	Healthcare Information and Management Systems Society		
HL7 International	Health Level Seven International		
HPLC	High-Performance Liquid Chromatography		
HRC	The Pacific Health Research Committee and the Health Research Council of New Zealand		
ICC	Information, Concepts and Context		
ICD-11	International Classification of Diseases, 11 th Revision		
ICH	International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use		
ICMJE	International Federation of Orthopaedic Manipulative Physical Therapist		
IGPG	International Good Practice Guidelines		
IS	International Standards		
ISCMR	International Society for Complementary Medicine Research		
ISE	International Society for Ethnopharmacology		
ISO	International Organisation for Standardisation		
LAP	Latin American Parliament		
LLM	Large Language Model		
MMPT	Manual and Musculoskeletal Physical Therapies		
NS	Not Specific, But Nonetheless Highly Relevant to TCIM		
OMPT	Orthopaedic Manipulative Physical Therapies		